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Orthopaedic metallic implants are essential in providing structural support for diseased or 
destroyed joints or bones. Despite the biocompatibility of metallic implants used, the repair 
process may lead to poor outcome like fibrosis, inflammation and ultimately implant failure. 
Revision surgery to fix implant failure is costly and generally results in poor outcome which 
compromises the quality of life of patients. CoCr (Cobalt chromium) alloy was chosen for my 
studies as it is one of the most commonly used orthopaedic metallic implant known for its 
resistance to wear and corrosion. BMP-7 growth factor has been approved by the FDA for 
clinical use for orthopaedic applications. The equivalent BMP-7 peptide, derived from the 
knuckle epitope with a conjugated cysteine amino acid at the N-terminus was chosen as it offers 
promising anti-fibrotic properties by being able to down regulate TGF-β1, have anti-
inflammation properties and proven osteogenic properties. BMP-7 peptide can be covalently 
grafted onto the metallic surface using polydopamine binding for bioactive application. BMP-7 
grafted onto metal implant offers a promise of increased osseointegration, reducing fibrosis and 
chronic inflammation. There is a great clinical need to develop on site anti-fibrotic and anti-
inflammation materials to optimize metallic implant surgical success.   
 Fibrosis models in vitro are done using mouse fibroblast to simulate ECM (extracellular 
matrix) deposition. TGF-β1 (Transforming growth factor beta-1) is an important growth factor 
known to elicit the fibrosis phenomenon, producing the generally accepted marker of fibrosis, 
the myofibroblast (terminally differentiated fibroblast). Using mouse fibroblast cell lines, 3T3-
NIH, a model was created where fibroblast were seeded onto the CoCr metal surface to recreate 
the fibrosis model. TGF β-1 was introduced into the fibroblast over a period of 1 week to study 
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the effects of fibrosis. BMP-7 and its peptides are bound on the metallic implants using 
polydopamine chemistry and checked by X-ray photoelectron spectroscopy (XPS). 
Characterization of binding efficiency were done using fluorophore probe assay. Fibrosis down-
regulations were checked by real time RT-PCR, protein quantification and 
immunohistochemistry for expression of fibrotic genes and proteins. Both TGF-β1 and BMP-7 
growth factor activity were assayed via the Phospho-SMAD 2/3 proteins and Phospho-SMAD 
1/5/8 proteins respectively to confirm the efficacy of knockdown of fibrotic proteins and genes 
and the continued viability of the growth factors.   
 BMP-7 peptide is also tested for its effects on inflammation. Reduction of the 
development of chronic inflammation on the biomaterial surface would enhance direct bone-
implant bonding and improve implant survival and long-term results. Mouse macrophage RAW 
264.7 under lipopolysaccharide (LPS) induction was used as an in vitro model to study 
inflammation. The effects of BMP-7 peptide on inflammation were evaluated by measuring the 
expression of inflammatory markers like toll-like receptor-4 (TLR-4), tumor necrosis factor-α 
(TNF-α), and monocyte chemotactic protein-1 (MCP-1).  Immobilized BMP-7 peptide was 
found to be able to reduce inflammation markers like TLR-4, TNF-α and MCP-1. This reduction 
was checked with both real-time PCR and ELISA. Inhibition of BMP receptors by Noggin 
confirms that BMP-7 and unbound BMP-7 validates the anti-inflammation effect of BMP-7 
peptides. BMP-7 signaling pathway activation was shown by the presence of phosphorylation of 
Smad1/5/8. Utilizing the reactivity of polydopamine films to immobilize BMP-7 peptide onto 
metal substrates may provide a promising approach for applications in situations where reduction 
of inflammation around implants would be beneficial in improving surgical outcome, bone 
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CHAPTER 1 Introduction 
1.1 Scope of Problem 
 The demand for knee-replacement and hip replacement surgery are increasing in the 
future [1] owing to a physically active ageing population. Metallic orthopaedic implants are the 
biomaterials of choice used to replace musculoskeletal defect and treat diseases like end-stage 
osteoarthritis. Orthopaedic metallic implants like total hip replacements [2] and total knee 
replacements [1] are essential in providing structural support for diseased and destroyed joints or 
bones. Despite the biocompatibility of metallic implants used, the repair process may lead to 
many problems [3] like septic loosening and aseptic factors like fibrosis, inflammation [4] and 
other complications [5]. This challenge represents real clinical needs as revision surgery to fix 
implant failure is costly and is generally of poor outcome which compromises the quality of life 
of patients especially physically active patients [6]. The response of the body to the metal 
implant can be modulated against negative reaction to ensure optimum or full functional 
integration. Metal on metal joints showed worse outcome especially uncemented ones which 
undergo more revision surgery [2]. Hence there is a need to improve the performance of 
cementless metal joints. 
 CoCr (Cobalt-Chromium) alloy was chosen for my studies as it is one of the most 
commonly used orthopaedic metallic implant in replacing bones and joints. However, cobalt 
chromium is also known to shown some non-ideal body reaction like inflammation and fibrosis 
when in contact bone tissue [7]. CoCr particularly if it’s metal on metal articulation have higher 
failure rates statistically [2] and have been implicated in adverse soft tissue reaction [8]. Fibrosis 
on metal-on-metal implants are reported and controversially called Pseudo-tumour [9]. 
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Inflammation and immune reaction have been reported in pseudo-tumours surrounding CoCr 
[10]. 
1.2 Aims  
 The main scope of this project is to reduce excessive fibrous tissue encapsulation and 
chronic inflammation, generated by macrophage/monocytes on the surface of metallic implants. 
The hard surface of metals offers an anchor to attach these factors that can modulate cells or 
tissues in direct contact with the metal. Growth factors or its equivalent peptides can be 
covalently grafted onto the metallic surface using polydopamine binding to promote osteogenesis 
so that the implant can be surrounded by bone. Therefore using immobilized factors can confer 
long term functionality of the implant.  
 The main thrust of this project is to use molecular biology tools to study, characterize the 
modulation of cellular response to metal implants on in vitro models. Thus the scope of this 
project is to use established cell lines to model the specific cellular responses to metal, linker and 
BMP-7 peptide. First, the validation of the in vitro models and functionalization of BMP-7 
peptides are tested. The aim of my project is to use BMP-7 peptide and immobilized it on CoCr 
surface as a bioactive strategy to study 
1) osteoblast activity on CoCr surface 
2) fibroblast activity on the CoCr surface 
3) macrophage/monocytes activity on CoCr surface 
1.3 Hypothesis  
 Therefore based on the above premises, functionalized BMP-7 peptide is hypothesized to 
be covalently grafted onto the surface of CoCr implant. It is hypothesized that covalently grafted 
BMP-7 peptides would modulate against inappropriate host responses. 
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1.4 Scope  
 In chapter 2, the literature review covers the concepts, the scope; current understanding 
of the problem and outlook of the field will be addressed. It answers why cobalt chromium is 
chosen as the biomaterial for my studies. Cobalt chromium is used chiefly in total hip 
arthroplasty and resurfacing. The studies will also cover why BMP-7 peptide was chosen and 
used as an anti-fibrosis and anti-inflammation bioactive factor. 
  In chapter 3 covers the preliminary studies and validation of the methods used. This 
chapter also introduces the in vitro models and the materials used.  Chapter 3 also showed results 
which demonstrated why cobalt chromium is chosen as the biomaterial for my studies. Chapter 4 
covers the study to validate the functionalization of BMP-7 peptides on CoCr surface and the 
ostegenicity of the peptide vs. the growth factor and its controls. Chapter 5 covers the study of 
anti-fibrosis properties of BMP-7 peptide. In this chapter, a model using mouse embryonic 
fibroblast cells were seeded on the functionalized CoCr. Gene and protein expression, cell 
proliferation, MTT assays were used to study the effect of BMP-7 peptide on fibroblasts. Chapter 
6 investigates the anti-inflammation properties of BMP-7 peptides. In this chapter, mouse 
macrophages/monocytes were used and then tested for the levels of inflammatory cytokines and 
chemokine profile. Chapter 7 summarizes the project and novelty of the studies and clinical 
application. What new knowledge is gained and what assumptions are challenged. Chapter 7 is a 







CHAPTER 2 Literature Review 
 
2.1 Metal Implants for Bone Replacement 
 Metals in orthopaedic surgery are used as a biomaterial to replace lost, damaged or 
diseased bones in human adults and children. Biologically, metallic biomaterial replaces the 
original musculoskeletal structure and mechanically provides immediate support to resist loading 
upon implantation into the body [11]. Thus, metals as a biomaterial satisfies the above mentioned 
biomechanical and biomedical properties to provide good long term clinical outcome [11]. Metal 
implants owing to its density compared to organic implants, is easier to diagnose and monitor 
clinically. Clinical tools like X-ray and CT (computed tomography) scan can be used to monitor 
mechanical and biological breakdowns at the earliest possible time point.  Additionally, metals 
with prefabricated dimensions and standard sizes allows surgeons to custom fit the implant to 
minimize surgical trauma, hence a more aesthetically pleasing outcome [11].  As a result, metal 
implants are used in orthopaedic surgery as a biomaterial replacement of choice for bone tissue.   
 Metal implants are used since the 1950s and have gradually been improved over time for 
better integration into surrounding skeletal tissue. Metals are very important as orthopaedic 
biomaterials for  treating fractures [12], correcting deformity (i.e. varus/valgus knee), replacing 
cancerous bone and used as materials for total joint arthroplasty (i.e. total hip replacement and 
total knee replacement) [13]. The roles of metal as a biomaterial to replace bones are 
summarized in Fig. 2.1. Much of the work on metallic implants has also been also been perform 
in the field of dentistry in which mandibular bone coming into contact with metals. The most 
commonly used metal implants are stainless steel, titanium and cobalt chromium [14]. Unlike 
dental applications, metals are used in orthopaedic surgery prioritized load-bearing properties 
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like strength and corrosion resistance [15]. The most common application of metallic implants in 
orthopaedic surgery is the treatment for end-stage osteoarthritis [16]. Therefore, research to 
improve biocompatibility of these two metallic alloys and minimized adverse body reaction for 
clinical use are important issues in orthopaedic surgery.  
Figure 2.1 Metal as a biomaterial in orthopaedic surgery [11]. 
   
2.2 Orthopaedic Joint Implants  
 Titanium and cobalt chromium alloys are used in orthopaedic surgery either alone or a 
combination of the two alloys as separate components of an implant. For example, total knee 
replacement (TKR) prosthetics (Fig. 2.2) and total hip replacement (THR) prosthetics (Fig. 2.3) 
used CoCr and Ti. Both CoCr and Ti alloys have their advantages and disadvantages and can be 
combined by the medical device manufacturers for use by surgeons. On the one hand, Ti alloys 
are roughly 15% softer than CoCr alloys [15, 17], hence that Ti alloys have relatively poorer 
frictional and wear properties. As a result, Ti alloys are rarely used in weight bearing surfaces 
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where hardness and resistance to wear are crucial like femoral heads [15, 17] or used in hip 
resurfacing (Fig. 2.4), for example the Birmingham hip resurfacing device. On the other hand, 
the superior resistance to corrosion of Ti alloys allowed it to be used ubiquitously in non–load 
bearing surface components (i.e. stems, porous coatings and femoral necks) rather than CoCr or 
stainless steel. Finally, titanium alloys with axial and torsional stiffness approximate to those of 
bone compared to other alloys [15, 17] results in less stress shielding of the bone.  
 
 
Figure 2.2 Metal on metal TKR (total knee replacement). CoCr is usually used in the femoral 
portion as a replacement of cartilage. Uncemented portion may result in fibrous layer. The tibial 




Figure 2.3 Hip prosthesis for THR (total hip replacement) [18]. The Femoral stem is usually 
made of Ti which is cemented or uncemented. The Acetabulum portion of the hip is usually 
made of CoCr or Ti. 
 
 




2.3 Clinical Strategies of Implants to Bone Fixation 
 Many physical or mechanical strategies are employed to fix metal implant to existing 
bones in the orthopaedic surgical theater. Most commonly used are adhesives like bone cement 
which is a chemical used to bond metal implants to bone to achieve early strong fixation. Bone 
cements works by filling the gap of implants directly bone via rigid fixation. Adhesives and 
glues works by molecular attraction to allow it to attach to the surface. Cements on the other 
hand, mostly work through mechanical interlocking. 
 
2.3.1 Bone Cements 
 Clinically, bone cements and bone adhesives are used primarily in the fixation of 
fractures, the fixation of prostheses and the repair of defects.  The cements are in the initial phase 
are liquid or plastic which work via conformation to the irregularities in the substratum, thereby 
creating better bonding on rough surfaces. A common bone cement, PMMA 
(Polymethylmethacrylate) forms mechanical bond rather than a chemical bond with bone thereby 
creating, a weak bone-polymer joint [19]. However, there are problems associated with bone 
cement [20], namely cement voids/gaps between bone and implant and septic infections [21]. 
This cytotoxicity of the bone cement also results in wide zones of necrotic osteocytes that recruit 
macrophages and monocytes leading to inflammation and thus increasing bone resorption.  The 
body reacts by rapidly encapsulating the cemented surface from the bone by formation of non-
adhesive fibrotic capsule [19].              
 There are other strategies to bind metal to bone without bone cement. In a study using 
national registry of data of Wales and England, there is slightly better survival rate of revision 
surgery following cementless hip and knee surgery [22]. This study suggested that revision 
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surgery of cementless hip and knee results in higher survival rate. Another study suggested that 
cementless press-fit condylar total knee arthroplasty results in less revision surgery [23]. Despite, 
achieving a weaker early fixation and bone loss [24], cementless fixation can avoid the toxic 
effects of cement on the body. In addition, cementless fixation also retains sufficient bone stock 
for revision, and allowing earlier treatment of post-operative infections [25].  
 Other strategies to bind metal implants to bone are the use of bone mimics. Bone mimics 
include; coatings made of inorganic minerals, plasma spraying, and cements or particulates 
comprising a variety of calcium based salts, chiefly calcium phosphates, carbonates or sulfates. 
The biomimetic strategy relies on tricking the osteoblasts and ultimately the bone to encapsulate 
the metal implant [11]. In real clinical situations however, these mineral/salt coating are brittle 
and weak in practice causing peeling and cracking. This in turn strongly triggers secondary 
foreign body reaction and inevitable failure of the implant [11].  Owing to these limitations to 
bind metal implants to bone, there is a strong interest in tissue engineering to use bioactive 
factors to accelerate osseointegration of metal implants.  
 
2.4 Osseointegration 
 Osseointegration is the ideal fate of a fully integrated implant into the bone tissue. The 
concept was first described by Per-Ingvar Brånemark in the 1970s and the scientific community 
fully accepted as the phenomenon of ideal tissue reaction to metallic implants a decade later [26]. 
Osseointegration can be defined as the direct structural and functional connection between 
ordered, living bone and the surface of a load carrying implant. As such, osteoblast or bone 
forming cells should be the predominant cells at the surface of the implant (Fig. 2.5). This is the 
ideal outcome with a well-functioning implant [27]. The achievement and upkeep of rigid 
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implant fixation to host bone especially orthopaedic applications requiring major load-bearing 
function like joint replacement implants are required for successful bone interfacing [11]. This 
observation was described originally by Brånemark based on radiographs, light microscopic 
observation and electron microscopy (scanning and transmission) proofs [27].  
 
 
Figure 2.5 Schematic of localized sections of interfacial zone, showing osseointegrated tissue 
adjacent to implant surface. Osseointegration is more likely to be achieved with greater implant 
stability [27, 28]. 
 
2.4.1 Osseointegration of Metallic Implants 
 The bone-cementless implant strategies include those coated with bioactive factors at the 
surface, these results chiefly via mechanical interlock of bone (or called press-fit) and 
biomaterial. Typically, press-fit is used by surgeons where good adjacent bone is found in the 
patient (non-osteoporotic bone). Bone cementless implants are recently being employed as this 
technique possessed the ability to osseointegrate quickly. Hence, this will lower the risks 
excessive relative displacement at the host–bone interface a result from inadvertent early forces 
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will act on the implant, which may discourage osseointegration [11]. Cementless implant shows 
good longevity but the early fixation to the bone is problematic [29]. 
 The main factors that affect the rate of osseointegration or the strength of fixation are; 
implant surface, surface chemistry, the vascularity or host site osteogenic potential, and the 
initial stress/strain field [11]. The surface chemistry modification offers various bioactive factors 
to be coated to promote osseointegration to affect press fit, and ultimately osseointegration.  
 
2.5 Union of Bone and Metal Implants 
 Metal implants can become osseointegrated in bone via three different mechanisms; 
osteoconduction, bone formation, and bone remodeling. Osteoconduction and bone formation 
can play an important role in treatment outcomes which can be manipulated. The design of 
implant surfaces can be optimized to promote osteoconduction and bone formation [11]. 
  Osteoconduction can be defined as the movement and the differentiation of pre-
osteogenic cells, like pericytes towards osteoblasts [30]. Osteoconduction promotes contact 
osteogenesis (bone formation) on the surface of the metal implant. Bone formation and union 
with metal implants can be divided into contact osteogenesis and distance osteogenesis. The new 
bone tissue growing on the implant surface is called contact osteogenesis but in distance 
osteogenesis, the bone forms from the surface of old bone in an appositional manner toward the 
implant surface [30].  
 The surface of the implant must be colonized by osteoblast prior to bone matrix 
formation can start as bone tissue is absent on metal implant surface upon implantation. In fact, 
bone formation is similar to bone remodeling; each having a resorption surface of old bone 
which is presented with osteogenic cells, from which new bone can be laid down. On the one 
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hand, bone initially at these sites by differentiating osteogenic cells or new bone formation, i.e. 
contact osteogenesis [11]. On the other hand, in distance osteogenesis where there are gaps 
between bone and implant, new bone is synthesized on old bone surface at the implant interface. 
The bone surfaces supplies a colony of osteogenic cells that can secrete new matrix that migrates 
onto the implant where ultimately the implant becomes covered by bone [11]. 
 Therefore, the early stage of implantation of the metal on the bone is crucial where the 
body's initial response to a foreign object [30]. Bone remodeling is a late stage healing primarily 
control by biologically by osteoclast and osteoblast activities. Thus, factors that can influence the 
biology of bone favorably to adhere onto the surface of metal implants appear to be important in 
the success of osseointegration. 
 
 
Figure 2.6 Time factor of cellular response is crucial cell implant interfacing. Bioactive factors 
must coat the surface of the implant at the beginning/early phase of healing to stimulate 
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important cellular activities or processes [11]. This is to avoid complications like excessive 
inflammation or fibrosis. Fibrosis is characterized by matrix secretion which occurs from within 
24 hours to months. 
 
2.5.1 Time-Line for Metal Implant and Biological Interface 
 Strategies using bioactive factors to improve osseointegration have the greatest chance at 
success at the very beginning of the healing process. The start of the healing process is when 
bioactive factors can be employed ideally to program particular cell type population to transplant 
onto the implant interface and transform these cells into bone-forming phenotypes [11]. This 
strategy becomes less effective when bioactive factors are introduced subsequently in the healing 
process. Once biomineralization or ECM deposition is initiated by the cells on the implant 
surface, (Fig. 2.6) there is little that can be added to the process [11]. 
 
2.5.2 Criteria for Successful Implant Placement into Bone 
 Important conditions of the implant-bone tissue system are crucial in deciding positive 
clinical outcomes: (1) implant material(s) and surrounding tissue(s), (2) the interface region 
between tissue and the implant, and (3) the reaction of the implant and its degradation products 
on the systemic and local tissues. Despite the interfacial zone is composed of a relatively thin 
(<100 μm) layer consisting of heterogeneous metallic oxide, proteins, and connective tissue, it 
has an effect on the maintenance of interfacial integrity. Finally, implant integration is dependent 
on the patient’s overall medical status, the surgical techniques used, and the extent and time 




2.6 Surface Chemistry and Biologic Response 
 Another complication is that functional implants may degrade or wear off over time, 
leading to the creation of micron-or submicron particulate debris that may incite both local and 
systemic biologic responses. Titanium alloys with its passive oxide layers are generally well 
biocompatible or well accepted by the body. Metal may also release ions which can have side 
effects on the human body though can be tolerated physiologically in trace quantities [27].  Local 
accumulation of material around an implant may include membrane bound ions released due to 
wear or fatigue processes or insoluble reaction products. Excessive metal ion accumulation can 
lead to metallosis or tissue discoloration and also to reduced phagocytosis and increased 
cytotoxicity.  
 The interfacial area between the surrounding tissue and the implant is hence the most 
crucial entity in determining the biologic response to the implant. The positive outcome of the 
implant integration depends on its bulk and surface properties, tissue trauma during surgery, the 
site of implantation, and motion at the implant-tissue interface. Lastly, the type and orientation of 
cells adhering to metal surfaces is affected by the microscopic geometry/topology of the 
substrate surface [27]. 
 
2.7 Problems with Aseptic Loosening of Joints 
 Besides the more common bacterial infection, metallic implant material can loosen owing 
to various factors mainly biological (septic and aseptic) and mechanical [3]. Some of the 
common biological factors associated with aseptic loosening [31] are inflammation owing to 
metallic debris or ions, insufficient osseointegration and fibrous capsule formation. The above 
problem can degenerate into other problems like osteolysis, implant failure which require 
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revision surgery to remove the failed implant. Mechanical factors are in the implant designs, 
chiefly sizing problems, breakage and malpositioning [3]. 
 
2.8 Fibrosis 
 Fibrosis or fibrous encapsulation may negatively affect the implant function. Fibrosis is a 
not uncommon result of the soft tissue repair surrounding the implant (Fig. 2.7). The upstream 
event that leads to fibrosis is inflammation where macrophages and neutrophils are present 
around the implant area. These inflammatory cells secrete cytokines and chemokines which 
recruit and cause proliferation of fibroblasts and endothelial cells; both are repair cells.  These 
cells promote events like angiogenesis (neovascularization), ECM deposition, and remodeling, 
all which are processes necessary for the wound healing and tissue regeneration [32]. The end-
point healing process is generally fibrous encapsulation, a type of response which serves to 
protect or isolate the body from the implant.  
 Fibrous encapsulation is also a type of foreign body reaction. This phenomenon is trigger 
in response to almost every implanted biomaterial and includes overlapping stages of both 
wound healing and tissue repair. Generally, rougher surface of metals can increased the 
biomechanical characteristics of the bone-implant interface whilst minimizing fibrous 
encapsulation of implants to certain extent. Despite these advances, fibrosis still constitute major 
clinical problem [5] and is considered to be a significant issue in orthopaedic and dental implant 
treatment strategies [11]. 
 Repair at the implant sites involve two different outcomes: 1) replacement by fibrous 
capsule (connective tissue) or 2) regeneration (replacement of injured tissue via parenchymal 
cells of the same type). These outcomes are generally determined by i) proliferative capacity of 
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cells in the tissue with the implant and the extent of wound/injury as it relates to the destruction, 
or ii) persistence of the tissue framework of the implant site [33]. Perfect restoration of normal 
structure/function hypothetically occurs only in tissues consisting of stable and labile cells. Other 
injuries to tissues composed of permanent cells may give rise to fibrous capsule formation with 
very little restoration of the normal tissue or organ structure. Tissue composed of stable cells 
(e.g. parenchymal cells of the liver, kidney and pancreas), mesenchymal cells (e.g. fibroblast, 
smooth muscle cells, osteoblast and chondroblast) and vascular endothelial and labile cells (e.g. 
epithelial cells and lymphoid and hematopoetic cells) may also follow this pathway to fibrosis or 
may undergo resolution of the inflammatory exudates, leading to restitution of the normal tissue 
structure. Retention of the framework may lead to restitution of the normal tissue structure, 
whereas destruction of the framework most commonly leads to fibrosis. With total joint 
prostheses, the important interfaces are those involved in fixation of the components, i.e. metal, 
ceramic or bone cement with bone. It is these interfaces where inflammatory responses, 
provisional matrix formation and /or healing responses may compromise the ultimate function of 
the total joint prosthesis. The extent of provisional ECM formation is an important step as it is 
related to wound healing by primary union or secondary union. Primary union wound healing 
occurs when there is no space or minimal space between bone and implant whereas secondary 
union wound healing occurs when a large space, providing for extensive provisional ECM 
formation, is present [30]. 
  
2.8.1 Fibrosis as an Aid to Implant Integration 
 Material designers have taken advantage of this phenomenon of fibrous capsule 
formation by creating a porous-surfaced metal designs for implant stabilization in bone [34].  
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This phenomenon can be taken advantage of by designing porous biomaterials inoculated with 
parenchymal cells or porous biomaterials implanted into bone [33]. This is in contrast to more 
conventional threaded or smooth-surfaced designs. The enmeshed fibrous tissue into the porous 
implant creates favorable long outcome as an anchor onto the bone. Nevertheless, the use of 
three-dimensional or porous metal scaffolds for skeletal tissue engineering has been limited 
because of their lack of mechanical strength and firm structures and their inherent instability 
when loaded [35]. In short, porous design compared to solid metal is also a compromise on 
structural integrity and can be used in limited applications. Inoculated porous implants with 
parenchymal cells can result in donor site morbidity and low bioavailability of growth 
factors/nutrients. 
 
2.9 Fibrosis as a Common Problem in Implant Failure  
 The question then becomes why fibrosis is bad or good. Generally, excessive fibrosis is 
bad, because it seals of the area between the implant and bone, which effectively cuts off 
nutrients supply [17].  Furthermore, metal implants in the body often cause formation of a poorly 
vascularized fibrous capsule that inevitably lead to implant failure [36]. Cells trap at the implant 
and also owing to lack of general housekeeping of tissue functions like removing apoptotic or 
necrotic cells which can also promote inflammation [7]. Not only that the ECM secreted by 
fibroblast is different from the bone matrix formation generated by osteoblast, i.e. fibroblast 
cannot deposit bone or ossification, whereas osteoblast can. Over long term, this ECM layer may 
cause the implant to slide against implant (micro-motion) which one of the major cause of 
aseptic loosening. Osseointegration vs. fibrous encapsulation formation depends on timing and 
micro motion of the implant in the host. Fibrosis generally occurs in smooth/threaded surface 
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[37] and is generally bad [38]. Surface of material is important in osteoblast, generally rough 
nano surface more favorable for osteoblast [39]. 
 Clinically, fibrous encapsulation has been known to occur to implants made of steel, 
usually with the presence of a liquid filled void between the tissue and implant [34]. This was 
previously thought that cells not adhering adequately to the surface, resulting in a destabilization 
of the implant, an inhibition of tissue regeneration and repair as well as increasing the chances of 
infection. This ultimately leads to the rejection and failure of the implant [40]. Fibrosis is even 
implicated in the development of cancer [41] and pseudotumours [42]. Pseudotumour is a 
controversial disease, that is reported in failed metal on metal total hip replacement [10] with an 
increasing risk factor for women [43]. Biomaterial-induced inﬂammation and foreign body 
response is one of the important formation of fibrosis. 
 Generally thinner the fibrous layer around the implant is the resultant of a more 
chemically inert material. Nevertheless it is important to realize that the thickness of the fibrous 
layer can also be affected by motion and fit at the interface. If a nearly inert implant is loaded 
such that interfacial movement occurs, the fibrous capsule can become several hundred 
micrometers thick, and the implant may loosen very quickly. Loosening generally leads to 
clinical failure for a variety of reasons, including fracture of the implant, of the bone, or of the 
bone adjacent to the implant [15]. 
 Different metals exhibit different properties when interacting with bone to osseointegrate. 
For example, steel and cobalt chromium alloys have no osteoconductive power because these 
metals do not readily form an oxide layer. Therefore these metals are isolated from bone by a 
layer of collagen and the underlying structures of bone remained unchanged [44].  
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  Subsequent to injury or surgical implantation, cells around the implants may show signs 
of growth and differentiation transformations. For instance, major cellular transformations are: in 
smaller cell size or functions (atrophy), in bigger cell size (hypertrophy), increase in cell number 
(hyperplasia), and cell type changes (metaplasia). Other cellular transformations are changes in 
stoppage in cells manufacturing one family of proteins but start manufacturing another protein 
(phenotypic change) or even excess protein production. The latter phenomenon may explain why 
cells secrete different types of collagen and ECM proteins seen in inﬂammation and in ﬁbrosis. 
Some of the causes of atrophy of the cells surrounding the implant may be a decreasing workload 
(e.g. stress-shielding by implants), insufficient nutrition (e.g. ﬁbrous capsules isolating the 
implant) and diminished blood supply [45]. 
 
2.10 Other Origins of Fibroblast 
 Myofibroblasts are generally the main protagonist in fibrous encapsulation of metal 
implants. Despite having a common overexpression of ECM link amongst the various fibrosing 
organs/problems, few studies hitherto have looked into the role of the ECM environment in the 
genesis of fibrosis. Myofibroblast, a fibroblast which produces aberrant ECM appears to be the 
terminal differentiated fibroblasts in fibrosis.  Myofibroblasts are morphologically stellate-
shaped, contractile and possessing filament-laden structure. Myofibroblasts also expresses large 
quantities of α-smooth muscle actin (α-SMA) and vimetin. Myofibroblasts can result from a 
gradual transformation of tissue-resident fibroblasts, epithelial-mesenchymal transition (EMT) 
and bone marrow derived fibrocytes [46]. There also appeared to be a link between inflammation 






Figure 2.7 Fibrous integrated tissue adjacent to implant surface. Excess tissue-implant-relative 
motion may result in fibrous-integrated tissue [27, 28]. 
 
 
2.11 Fibrotic Marker 
 Fibrosis is generally associated with high levels of extra cellular matrix (ECM) proteins. 
These ECM proteins are the ubiquitous collagen 1 and fibronectin. Fibrosis is also associated 
with higher expression of myofibroblast, a differentiated fibroblast [47]. The marker of 
myofibroblast is the α-smooth muscle actin [48] or ACTA2 (Alpha Actin-2) [49]. The expression 
of these markers, either mRNA or proteins allows the measurement of the extent of fibrosis. 
In clinical terms, osseointegration is the host bone responding in a safe, predictable, and 
versatile manner to surgical placement of an implant in a sterile wound, with a healing cascade 
leading to interfacial osteogenesis and mechanical stability of the implant [27]. Because a stable 
interface must be developed before loading, it is desirable to accelerate tissue apposition to 
implant surfaces [27]. Material developments that have been implemented in clinical practice 
include the use of surface-roughened implants and bioactive ceramic coatings [27]. Other 
techniques include electric stimulation, bone grafting and recombinant growth factors [27]. Less-
than-optimal surgical techniques or implant surface chemistry and relative motion between the 
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implant and tissue can lead to a thicker zone of proteoglycans, soft connective tissue, and 
disordered bone [27]. 
 
2.12 Inflammation  
 Inflammation is the body’s response to infection and foreign objects in the body. There is 
some interplay of inflammation and fibrosis in the healing environment of metallic implant, 
which suggest that fibrosis is one of the downstream or outcome of inflammation (Fig. 2.8) [46]. 
Generally excessive inflammation or chronic inflammation is a negative outcome of body 
responses to implant. In addition, wear particles like ions metal debris can illicit immune reaction 
like inflammation and allergy [50] to these agitating factors. Modulating these two outcomes is 
essential for successful tissue engineering or implant integration into the body.  
 Metallic ions and debris can also be generated from articulating surfaces like total hip 
devices and total knee devices [4]. Metallic debris like Cobalt Chromium has been known to 
elicit inflammation. Necrosis and inflammation have also been reported on failed CoCr implants 
[51]. These necrotic and inflammatory changes in metal-on-metal implant failures are resultant 
from CoCr particles and generate immune responses.  
 Fibrosis have both a fibrotic element and an inflammation element in its progression [52]. 
Inflammation is an upstream foreign body reaction (FBR) occurring at the tissue/metal implant 
interface that initiates wound healing process and reduces infection [53]. Inflammation, chiefly 
mediated by macrophages and monocytes secretes many chemokines and cytokines which in 
turn, attract fibroblasts, stimulate fibroblasts proliferation and causes fibroblasts to differentiate 
to myofibroblasts. Fibroblast, the main cellular protagonist in fibrosis, can come from many 
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sources. Fibroblast chiefly originates from bone marrow fibrocytes, fibroblast proliferation and 




Figure 2.8 The link between fibrosis and inflammation [46].   
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2.13 Treatment for Fibrosis 
 
 Fibrosis is also a major problem in other human tissues besides peri-implant fibrous 
encapsulation. Fibrosis is involved in many organs like lungs, liver, kidney, eye and other 
disease like Crohn’s disease [54] where an individual’s genetics [55] also play a role. Owing to 
the importance to treat fibrosis, many drugs are studied and developed. There are numerous 
treatment strategies to reduce fibrosis. Many drugs are used to decrease collagen synthesis, 
preventing myofibroblast movement, decreasing TGF-β1 levels, degrading ECM proteins and 
decreasing inflammation by reducing TNF-α expression. So far, TNF-α and TGF-β1 reduction 
shows great promise as they target initial reactions of the body towards metal implants. 
Targeting these cytokine and growth factor allows modulating the body’s reaction to the implant.  
 Currently, there is no satisfactory cure for fibrosis. However, much of the work on 
treating fibrosis have been done on in vitro models using cell lines [56] as fibrosis affects many 
tissues and cell types. Most in vitro models uses TGF-β1 to stimulate fibrosis as TGF-β1 is 
strongly implicated in fibrosis via ECM proliferation in many cell types [57]. In vivo models use 
bleomycin, a profibrotic drug that simulates ECM proliferation, in the lung and the skin [58]. 
Much of the studies on fibrosis are inter-disciplinary and much of the work has been done to 
treat Crohn’s disease [54]. There are many types of drugs used to treat fibrosis, with the aim to 
decrease collagen synthesis, degradation of ECM, blocking TNF-α and inhibiting TGF-β1 
pathways as summarised in Table 2.1. By far, the most promising groups of drugs are the ones 
that target TGF-β1 pathways as it directly affects fibrosis. Of these, BMP-7 is one of the anti-




Types Examples Benefits Disadvantages 
Corticosteroids  Dexamethasone Decrease collagen synthesis Side effects and decrease 
wound healing 




Slows down fibrotic process Immunosuppressive 
TNF-α blocking agents infliximab  
 
(In vitro studies) Modulating Myofibroblast 
movement, decrease collagen production 
and decrease FGF, VEGF, TIMP-1 levels 






(in vitro studies) 
Decreases TGF-β1, monocyte, 
chemoattractant protein-1, macrophage, 









inhibitors), ARB  
 
Decrease Collagen synthesis and  TGF-β Works on renal and cardiac 
so far 





2. GC1008,  
3. αvb6 inhibitor, 
4. ALK5 inhibitors,  
5. HGF,  
6. BMP-7,  
7. Decorin  
8. Tyrosine-kinase 
inhibitors:   
     -Imatinib, Dasatinib, 
Nilotinib 
1. Monoclonal antibody blocking TGF-β1 
isoform 
2. Pan specific anti-TGF-β monoclonal 
antibody 
3. TGF-β thru inhibition of αvb6  
4. Abrogated fibroblast activation 
5. Natural inhibitor of SMAD2/3 
translocation in fibroblast 
6. Natural inhibitor of fibrocyte 
proliferation thru SMAD pathway. 
7.  Decrease collagen synthesis and 
downstream TGF-β  thru decrease in 
SMAD2 level 
8. Modulates  fibroblast proliferation  thru 
inhibition of tyrosine kinase 
ALK 5 inhibitors has 






Degradation of ECM  
 
Works on renal cells/tissues 
inhibitors of  TIMP  
 
α2-macroglobulin, issue 
factor pathway inhibitor-2 
Degradation of ECM  
 
Works on renal cells/tissues 
Vascular endothelial 
growth factor blockade 
BIBF-1120  
 
Blockade of VEGF receptor , PDGF and  
FGFR  kinase activity  
 
Works on inflammation 
linked fibrosis and not EMT 
 
Table 2.1 showing current treatment of Fibrosis in Crohn’s disease [54]. 
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2.14 TGF-Beta 1 
 TGF-β1 (Transforming growth factor beta-1) is an important growth factor known to 
elicit the fibrosis phenomenon, producing the generally accepted marker of fibrosis, the 
terminally differentiated fibroblast-the myofibroblast [49]. TGF-β1 binds to the TGF-β1 
receptor/alk5 receptor to phosphorylate SMAD3 and SMAD2, which then together with SMAD4 
elicits the downstream pathway to activate fibrotic genes. BMP-7 on the other hand binds to a 
different receptor than TGF-β1 and BMP-7 is known to counteract the activity of TGF-β1 [59].   
 This activated BMP-7 receptor then phosphorylates SMAD1, 5 and 8 which together with 
SMAD 4 activate downstream gene expression. How BMP-7 inhibits TGF-β1 is through 
inhibition of SMAD3 via SnoN and Ski proteins (Fig. 2.9). Furthermore, BMP-7 pathway also 
competes with TGF-β1 for the binding of co-SMAD4. An important note is TGF-β1 must not be 
shut down completely as it had deleterious effects on cellular function [60]. BMP-7 opposes 
TGF-β1-mediated collagen induction in mouse pulmonary myofibroblast through Id2 [61]. 
 
2.15 BMP-7 Growth Factor 
 Recombinant BMP-7 growth factors have been approved for clinical use by the US FDA.  
However, FDA-approved usage of BMP-7 growth factors are restricted in the following 
indication: (i) treatment of acute tibial fractures treated with intramedullary fixation and (ii) 
treatment of long bone non-union [62]. BMP-7 growth factors have been used clinically for post-
surgical bone related treatments with a reported success of 82% [63]. In addition, BMP-7 growth 
factors has been reported to have both anti-fibrotic [54], anti-inflammation [64] and the clinically 
approved osteogenic [63] properties. The inhibition of TGF-β1 pathway of BMP-7 (Table 2.1) is 
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of great interest in our studies, as BMP-7 already is known and approved by FDA for use in 
orthopaedic surgery. 
 BMP-7 belongs to a family of BMPs or bone morphogenic proteins. Another name for 
BMP-7 is Osteogenic Protein-1 or OP-1. BMPs bind to the extracellular portion of the receptor I 
and receptor II as a ligand [65]. Upon binding of BMP ligand, the receptor I and II binds and 
phosphorylates downstream signaling proteins like the SMAD proteins, specifically SMAD-1, 5 
and 8 with co-SMAD-4 [66]. These SMAD complexes translocate into the nucleus to activate 
gene expression. BMP can also affect gene expression via the MAPK pathway independent of 
SMAD pathway [66]. However, BMP-7 is extremely costly to manufacture and unaffordable to 
most patients as a therapeutic agent. 
 




2.16 BMP-7 Peptides 
 There are now attempts to create biologics that mimic the BMP-7 bioactivity at a much 
significantly cheaper cost. BMP-7 growth factor offers promising anti-fibrotic properties by 
being able to down regulate TGF-β1 [54, 67]. BMP-7 anti-fibrotic properties were assayed for its 
ability to down regulate TGF-β1 induced fibrotic markers like ACTA2, collagen 1A1 and 
fibronectin [68]. In vitro models allowed a cost effective way to test for cellular response to the 
peptide of interest. In our in vitro model, BMP-7 peptide is attached to the surface of cobalt 
chromium via covalent binding using polydopamine (Fig. 2.10).  
 
 
Figure 2.10 Schematics for the bioactive strategy of coating BMP-7 peptide onto CoCr. 
  
2.17 Surface Modification to Confer Bioactivity  
 The performance of metallic implants can be significantly improved the use of 
biologically active coatings onto the surface to encourage the apposition of newly formed bone 
[69]. For example, these approaches uses inorganic (Calcium Phosphate) and organic (enzymes, 
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ECM components, growth factors, etc.) components of natural bone tissue, to affect 
osseointegration [69].   
 Bioactive surface with osteoconductive properties can prevent the formation of fibrous 
tissue bone-interfacing by osteoconductive as well as osteoinductive methods to deposit bone. 
Several surface functionalization methods like physical- chemical, morphologic and biochemical 
have been studied to solve the problems of bone integration. In our study however, bone 
apposition is one of the aspect of the equation. There is also a need to address non-ideal healing 
outcome like fibrosis and inflammation. Therefore, selecting a bioactive coating that bind anti-
fibrotic or anti-inflammation is an ideal outcome. 
 
2.18 Polydopamine Coating 
 Polydopamine a natural material originally isolated from sea-barnacles allows a nontoxic 
adhesion of biological/organic material onto inert material like metal, similar to barnacles 
attaching themselves to hulls of ships etc. In addition, there is limited number of bioactive 
ceramics that can be fused to living bone that prevents the formation of fibrous encapsulation 
[70]. Polydopamine is a promising chemical to be used. It can bind strongly to metal and is 
relatively non-cytotoxic. The work of binding growth factors have been used successfully for 
VEGF [71] and BMP-2 [72].  
 
2.19 BMP-7 Effects on Inflammation 
  Reduction of immune responses of macrophages on foreign implant material, 
particularly cobalt chromium implants is important in ensuring longevity of the implant. 
Excessive inflammation or chronic inflammation around the implant can degrade into fibrosis, 
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osteolysis and subsequent result in implant rejection. This was found by studies [73] that 
highlighted inflammatory related chemokine secretion is responsible for macrophage recruitment 
particularly MCP-1 [74]. Persistent macrophage accumulation around the implant creates a 
positive feedback on the release of inflammation cytokines. 
 Inflammation is a complex reaction by the body with many complex interconnected 
signaling pathways involved. Pro-inflammatory cytokine like TNF-α, chemokine MCP-1 and 
receptors like TLR-4 are used in our studies as these are some of the more common markers are 
used in medical research. BMP-7 effects on inflammation have been studied and established by 
other groups. And specifically related to our studies, Rocher et al showed that BMP-7 exerts its 
anti-inflammatory pathway by switching the macrophage into the M2 anti-inflammatory 
phenotype thereby decreasing the levels of TNF-α and MCP-1 [75]. Lee et al showed that BMP-
7 inhibits MCP-1 expression (one of inflammation markers) in human mesangial cells partly by 
inhibiting c-Jun N-terminal kinase activity and subsequent AP-1 activity [76]. Gould et al first 
showed that BMP-7 reduces basal TNF-α levels and TNF-α stimulated expression of the pro-
inﬂammatory downstream cytokines like IL-6 and IL-1β in a renal model [77]. Interestingly, 
Shimada et al showed that Traf-2 (TNF receptor associated factor-2) can cross talk with BMP 
signaling, and hence one way of BMP-7 may have an indirect effect on TNF-α secretion [78]. 
Related to our LPS model, Bobacz et al showed that TLR-4 inflammation is reduced and their in 
vitro study characterized the involvement of p38 MAPK, but not ERK-1/2, in LPS-mediated 
TLR-4 signaling in human articular chondrocytes [64]. The limit of our experiment is the use of 
LPS as a marker to induce inflammation which may not account for other complex 




CHAPTER 3 Coating of BMP-7 Peptide onto CoCr and Ti Alloys 
3.1 Introduction 
 The choices of metals for this study are the two most commonly used metal, cobalt 
chromium and titanium alloys. The titanium and cobalt chromium alloys are common 
orthopaedic biomaterials used for total hip replacement, total knee replacement and hip 
resurfacing. Preliminary studies serve to validate the model using in vitro seeding of cells onto 
the surface of the metal and the coating of polydopamine as a layer to bind BMP-7 peptide. Cells 
like human fibroblasts were seeded onto the metal to validate the fibrosis model and the seeding 
of human osteoblasts onto the metal. This is to provide an in vitro model to study fibrosis and 
osseointegration.  
 Cobalt chromium alloys contains elemental cobalt as the main element with various 
percentages of chromium element added, upwards of 30%, depending on the manufacturer or 
grade [14]. In order to improve corrosion resistance, varying trace amounts of carbon, nickel and 
molybdenum are also alloyed together with cobalt and chromium. This mixture depends on 
manufacturing grade and clinical needs but grades of 70% cobalt and 30% chromium are 
ubiquitous in orthopaedic applications. In orthopaedic surgery, CoCr alloys are used commonly 
on femoral heads, owing to its excellent hardness and resistance to corrosion [15, 17].  CoCr 
alloys are also used as a major material in total knee replacement devices [25]. Therefore, CoCr 
alloys are suitable as the metal of choice bearing surfaces. On the one hand, CoCr generally is 
also wear resistant and have excellent biocompatibility [14].  On the other hand, CoCr is very 
expensive to manufacture and requires expensive specialist tools to fabricate. 
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 The ubiquitous orthopaedic titanium alloy grade is titanium 64 or (Ti-6Al-4V). The 
numerical suffix and nomenclature specifies the percentage of the alloying elements of 6% (Al) 
aluminum and 4% (V) vanadium [14]. The addition of aluminum and vanadium gives the Ti-
6Al-4V alloy greater strength than elemental titanium. Titanium alloy display remarkable 
resistance to corrosion (relative to stainless steel) and possessed excellent biocompatibility [14]. 
Titanium readily forms an oxide layer (TiO2) by a process called passivation, allowing titanium 
alloy to be more resistant to corrosion [14]. As such, titanium alloys are usually used in 
orthopaedic plates, screws and nonbearing surfaces components of total join arthroplasty [15]. 
Finally, titanium has lower modulus of elasticity [79] relative to other metals and the oxide layer 
also aids in preventing the formation of fibrous tissue around the implant.  
 The BMP-7 peptide was synthesized to mimic an established sequence [80]. This BMP-7 
peptide was derived from the knuckle epitope of BMP-7 growth factor. This peptide was 
previously shown by Zouani et al to activate BMP-7 signaling by binding to BMP receptor II. 
This BMP-7 peptide was further modified with a cysteine tag and a MiniPEG (8-Amino-3, 6-
Dioxaoctanoic Acid, AEEA). Mini-PEG acts as a spacer to can be used to minimize the adverse 
effects of bulky labeling reagents and interference of non-specific binding. Adding Mini-PEG 
increases the molecular mass of the peptide, which can provide shielding from proteolytic 
enzymes [81]. A cysteine tag was added to the N-terminus of the peptide to keep interference on 
the functional activities of the peptide to a minimum [82].  
 The BMP-7 peptide was synthesized commercially. The purity of the peptide was 
checked using HPLC (High Performance Liquid Chromatography) and the 20 amino acid long 
peptide probe is tagged with a FITC (Fluorescein isothiocyanate) fluorophore. Mass 
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spectrometry is used to check for the different elemental composition of the peptide and the 
quality control of the synthesis of the peptides.  
 Therefore, preliminary studies were used to test if BMP-7 peptide can be coated on CoCr 
and Titanium alloy. The coating used is polydopamine [72] which was an established method to 
covalently bind BMP-7 peptide to the metallic surface. Scanning Electron Microscope (SEM) 
and Scanning Electron Microscope Energy-dispersive X-ray spectroscopy (SEM-EDX) were 
used to study the surface morphology and elemental composition of the in vitro model 
respectively. The surface morphology and topography of the metals [83] plays some role in the 
attachment of the cells. Fibroblasts [84] and osteoblasts were used as in vitro models or proof of 
concept. These preliminary studies serve as a model for subsequent studies.  
3.2 Method and Materials 
Materials 
 Cobalt chromium and titanium alloy foils were purchased from Goodfellow, UK. 
Dopamine (3,-4-dihyroxyphenylalanine) was purchased from Sigma-Aldrich, USA. 
Experimental dilutions were performed with ultrapure water (>18.2 MG cm, Millipore Milli-Q 
system). Human lung fibroblast (Wi-38) and human osteoblast (hFOB 1.19) were obtained from 
ATCC, USA. The cysteine-tag functionalized BMP-7 peptide, Cys-miniPEG-
TVPKPSSAPTQLNAISTLYF was synthesized by 1st BASE, Sg. The equivalent BMP-7 peptide 
probe, Cys-miniPEG-TVPKPSSAPTQLNAISTLYF-Lys-FITC was synthesized by 1st BASE, 
Sg. The purity was 94.52% as determined by reversed-phase high-performance liquid 
chromatography (HPLC) on a Venusil XBP-C18 column with an acetonitrile gradient in 0.1% 
trifluoroacetic acid in water, at a flow rate of 1.0 ml/min, with detection at 220 nm. The purity 
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was 96.12% as determined by reverse-phase high-performance liquid chromatography (HPLC) 
on SinoChrom ODS-BP column.  
Preparation of Substrates 
 CoCr and Ti foils were cut into dimension of 1 x 1 cm2. The CoCr and Ti substrates were 
cleaned for surface passivation as previously described [72]. The acid-treated substrates were 
then rinsed thoroughly with ultrapure water and polydopamine was coated to the surface of the 
CoCr substrates via immersion of the substrates in a 2 mg/ml solution of dopamine (10 mM Tris 
buffer, pH=8.5) overnight in the dark [72].The substrates were then rinsed with copious ultrapure 
water to remove the unattached dopamine and further dried under nitrogen gas flow [72]. BMP-7 
peptide were then coated onto the polydopamine grafted CoCr substrates and incubated 
overnight at room temperature in a humid atmosphere. Unattached BMP-7 peptide on the 
substrates were then washed away via three washes with sterile PBS (Phosphate buffered 
solution) and left to air dry in a sterile environment before use. In subsequent discussions, the 
substrates are denoted as CoCr (pristine cobalt chromium), CoCr-PDOP (polydopamine grafted 
CoCr) and CoCr-PDOP-BMP-7 peptide (BMP-7 peptide-coated, polydopamine grafted CoCr). 
Similarly for titanium, the substrates are denoted as Ti (pristine titanium), Ti-PDOP 
(polydopamine grafted Ti) and Ti-PDOP-BMP-7 peptide (BMP-7 peptide-coated, polydopamine 
grafted Ti).  
SEM-EDX 
 The CoCr and Ti substrates were prepared for analyses by coating the surface with 
platinum. The platinum coated substrates were then analyzed using a system of scanning electron 
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microscope (SEM) attached to an energy dispersive X-ray Spectroscopy (EDX); JEOL, model 
5600LV.   
SEM 
 Samples with cells were prefixed overnight in 3% glutaraldehyde solution (Sigma, USA) 
and then washed with 1 X PBS (Invitrogen, USA).  The samples with cells were then post fixed 
with 1% osmium tetroxide (Sigma, USA) for 2 hours at room temperature. The samples with 
cells were then dehydrated with increasing concentration of ethanol. The samples were then 
completely dried using critical point drying and then mounted on SEM stubs. Unmodified and 
modified CoCr substrates were coated with gold and the surfaces of the substrates were imaged 
using a scanning electron microscope (JEOL model JSM-5600LV). 
Tissue Culture 
 Human lung fibroblast Wi-38 (American Tissue Culture Collection, USA) were routinely 
cultured in 10% FBS (Fetal Bovine Serum) and 5% Penicillin/Streptomycin (Invitrogen) in 
DMEM (Invitrogen). The cells were incubated at 37oC in a humidified atmosphere of 5% CO2 
with the growth medium changed every 2 days. Trypsinized fibroblasts were seeded on top of 
coated/uncoated 1 x 1 cm2 CoCr placed inside a 24-well plate at 50,000/well in 10% FBS and 
100 μM of L-ascorbic acid (Wako, Japan). Cells were cultured and with/without the optimum 
concentration of 10 ng/ml TGF-β1 (BioVision, USA).  
 Human Osteoblast hFOB 1.19 (American Tissue Culture Collection, USA) were 
routinely cultured in 10% FBS (Fetal Bovine Serum) and 0.3 mg/ml G418 (Invitrogen) in 1:1 
DMEM ⁄ F-12 (Invitrogen). Trypsinized osteoblasts were seeded on top of coated/uncoated 1 x 1 
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cm2 CoCr placed inside a 24-well plate at 50,000/well in 10% FBS and incubated at 34oC in a 
humidified atmosphere of 5% CO2. The growth medium changed every 2 days. 
3.3 Results 
Preparation of Substrates 
 




Preparation of Substrates  
 Metal sheets were cut into 1 x 1 cm2 size (Fig 3.1). The metals were then treated with 
chemicals to allow passivation. The metals were then placed inside the wells of a 24-well plate 
for susequent in-vitro experiments (Fig 3.1). 
SEM-EDX of CoCr 
 
Figure 3.2 CoCr SEM-EDX: showing 30% Chromium and 70% Cobalt. 
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SEM-EDX of CoCr 
 The 1 x 1 cm2 CoCr sheets were checked using a SEM-EDX. The pristine CoCr sheet are 
coated with platinum and analyzed for its elemental composition. 
SEM-EDX of Titanium Alloy 
Figure 3.3 SEM-EDX of Titanium substrate. 
SEM-EDX of Titanium Alloy 
 The 1 x 1 cm2 Ti sheets were checked using a SEM-EDX. The pristine Ti sheet are 
coated with platinum and analyzed for its elemental composition. 
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Mass Spectrometry of BMP-7 Peptide 
 
Figure 3.4 Mass spec of the BMP-7 peptide. 
Mass Spectrometry of BMP-7 Peptide 
 The BMP-7 peptide is analyzed for its mass and the structure of the peptide. The 




HPLC of BMP-7 Peptide Probe 
 
Figure 3.5 HLPC of the BMP-7 peptide sequence 
HPLC of BMP-7 Peptide Probe 
 The HLPC profile of the BMP-7 peptide sequence with a FITC probe. 
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SEM of Titanium Coated With Polydopamine, Polydopamine-Peptide and Fibroblast 
 
Figure 3.6 SEM of titanium metal: A-Pristine titanium, B-Fibroblast attaching onto titanium, C-
Titanium coated with polydopamine, D-Titanium coated with BMP-7 peptide with 
polydopamine. 
SEM of Titanium Coated With Polydopamine, Polydopamine-Peptide and Fibroblast 
 These SEM pictures showed that pristine Titanium (A) is relatively grainy/rough in 
surface texture. Human fibroblasts were seeded onto the pristine titanium after 3 days and it 
showed fibroblasts did not attached very uniformly onto the titanium surface (B). Addition of 
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PDOP (C) increases the graininess/roughness surface texture of the titanium. Addition of BMP-7 
peptide increases the graininess/ roughness surface texture of the titanium (D).   
 
SEM of Cobalt Chromium Coated With Polydopamine, Polydopamine-Peptide and 
Fibroblast` 
 
Figure 3.7 SEM of cobalt chromium metal: A-Pristine CoCr, B-Fibroblast attaching onto CoCr, 




SEM of Cobalt Chromium Coated With Polydopamine, Polydopamine-Peptide and 
Fibroblast 
 These SEM pictures showed that pristine CoCr (A) is relatively smooth in surface 
texture. Human fibroblasts were seeded onto the pristine titanium after 3 days and it showed 
fibroblasts attached very uniformly onto the CoCr surface (B). Addition of PDOP (C) increases 
the graininess/roughness surface texture of the CoCr. Addition of BMP-7 peptide increases the 
graininess/ roughness surface texture of the CoCr (D).    
 
SEM of Human Osteoblast on Titanium and Cobalt Chromium 
 
 
Figure 3.8 Human osteoblasts seeded on titanium and cobalt chromium. 
SEM of Human Osteoblast on Titanium and Cobalt Chromium 
 These SEM pictures showed that human osteoblasts were seeded onto the pristine 
titanium after 3 days and it showed osteoblasts attached very uniformly onto the Ti surface (A). 
Human osteoblasts did not attach uniformly on the surface of pristine cobalt chromium surface 




 The surface morphology and elemental composition of the metals plays a role in the 
cellular response to metals. The metals were cut into 1x1 cm2 size for easy manipulation by 
placing it in a 24-well plate as an in vitro model (Fig. 3.1). The elemental composition (Fig. 3.2) 
of CoCr is 70% cobalt and 30% chromium and Ti (Fig. 3.3) is made of 95% titanium as 
determined by SEM-EDX. These are pure grade metals that are used as standard unmodified 
alloys for subsequent studies. The surface texture of titanium (Fig. 3.3) is rougher in morphology 
than CoCr (Fig.3.2). The peptide was generated by the manufacturer with the sequence of Cys-
miniPEG-TVPKPSSAPTQLNAISTLYF and a molecular weight of 2899.28 (Fig. 3.4). The 
equivalent probe of the peptide was checked by HPLC and the report was 96.12% (Fig. 3.5). 
These peptides are studied in further detail in the following chapters.   
 On the SEM pictures, the titanium surface (Fig. 3.6A) showed more grainy or rough 
surface as detected similarly by the SEM-EDX. In Fig. 3.6B, human lung fibroblast was seeded 
at 50,000 cells onto the metal surface but few fibroblasts have attached onto the surface. In Fig. 
3.6 C and Fig. 3.6 D polydopamine coating and additional BMP-7 peptide coating are seen here 
as increasing the overall surface roughness. CoCr (Fig. 3.7A) showed smooth surface as detected 
by SEM-EDX. In Fig. 3.7B, human lung fibroblasts can be seen to encapsulate the surface of 
cobalt chromium, which seem to agree with literature that smoother surface [27] encourages 
fibrous capsule formation. Conversely, smoother surface restricts osteoblasts attachment as seen 
in Fig. 3.8B. Titanium on the other hand exhibits better osteoblasts attachment as seen in Fig. 
3.8A. The limitation of different incubation of temperature and different type of culture medium 
of the osteoblast/fibroblast negates the studies using co-culture of fibroblast and osteoblast. For 
example human fibroblast grows well at 37oC in DMEM whereas osteoblast grows better in 34oC 
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in F12/DMEM [85]. Moreover, the human cell lines are relatively slow growing and perhaps 
mouse embryonic cell lines with a more prolific cell growth can be used in subsequent chapters. 
Finally, lung fibroblasts line is discarded as an in vitro model and mouse NIH/3T3 fibroblasts 
would be used. This NIH/3T3 fibroblasts line is an embryonic fibroblast line and is known to be 
activated by BMP-7 growth factor via BMP-7 receptors [86, 87].   
 The coating of polydopamine onto the surface of the Ti and CoCr are shown in Fig. 3.6C 
and Fig. 3.7C, respectively. The SEM photos showed grainier or rougher surface compared to 
pristine metals. However, more tools are needed to detect the elemental coating of polydopamine 
by means of (XPS) X-ray photoelectron spectroscopy which will be covered in chapter 4. 
Subsequent studies will use different cell lines to stimulate fibrosis and inflammation particularly 
on CoCr [7]. Based on the SEM image, fibroblast easily covers CoCr compared to titanium and 
hence offers a model to be investigated further. The addition of polydopamine increases the 
roughness of the surface, which was previously reported using AFM (Atomic force microscopy) 
[72]. Adding BMP-7 further increases the surface roughness. Cobalt chromium is chosen for my 
subsequent studies as the surfaces of cobalt chromium are readily encapsulated by fibroblasts 
and provides an in vitro model to the question of orthopaedic surgery for anti-fibrosis.  
3.5 Conclusion 
 The choice of metal to study in detail is CoCr as it has a smoother surface and fibroblasts 
can encapsulate the surface easily. This in vitro fibrous layer can be used as a model to mimic in 
vivo or clinical fibrous encapsulation of metallic implant. The polydopamine and the BMP-7 
coating suggest that it increases the surface roughness of the implant and may have some effect 
on cellular functions. The subsequent studies in the following chapters will address these issues. 
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CHAPTER 4 Osteogenicity of Bound BMP-7 Peptide vs. BMP-7 Growth Factor- An In 
Vitro Validation Study On CoCr 
 
4.1 Introduction 
 More economical BMP-7 peptides with osteogenic properties were developed due to the 
exorbitant cost of BMP-7 growth factors [80, 88]. The BMP-7 peptide of interest is a biomimetic 
derivation of the BMP-7 growth factor’s knuckle epitope of [80] which was covered in chapter 2. 
This BMP activates downstream BMP-7 signaling by vibrating BMP receptor II. 
 Immobilization techniques of bioactive factors are of great interest in order to create an 
interface between metal and bone to promote osseointegration. Various methods are developed 
to immobilize bioactive factors like enzymes/proteins using physical adsorption, physical 
entrapment, cross linking and covalent binding [89]. Polydopamine has attracted interest as a 
linker to coat the previously mentioned materials onto metallic surface [90]. Polydopamine, 
derived from the monomer dopamine undergoes polymerization under pH 8.5, serves as a 
coating has been proven to graft polymers, growth factors and peptides strongly on many 
surfaces via covalent bonding [91]. This is more so when CoCr metals used in this study lacks 
the rough surface/porous layer to anchor the cells. Therefore we now hypothesized that BMP-7 
peptides may be covalently grafted onto CoCr using polydopamine chemistry [91].  
Therefore in this study we aimed to address the above issues by the grafting BMP-7 
peptide onto the surface of CoCr and study its effects. A pH 8.5 aqueous dopamine solution was 
employed to autopolymerize a thin coat of adherent polydopamine onto the CoCr [72]. In chapter 
2, this BMP-7 peptide sequence [80] was tagged with at the N-terminus, cysteine amino acid, 
and with a mini-polyethylene glycol (miniPEG) as a spacer to produce a cys-tag functionalized 
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BMP peptide. This peptide is conjugated via thiol directed chemistry as previously described 
[92]. The conjugation of a cys-tag at the N-terminus and the MiniPEG spacers were added in 
order to reduce steric interference on the bioactivity of the BMP-7 peptide.  
The biological effects of the covalently bound and unbound BMP-7 peptides were then 
analyzed on mouse pre-osteoblast and the effects of the functionalized substrates for osteogenic 
properties were then investigated. In this study, we looked into the effects of immobilized BMP-
7 on CoCr alloy substrates functionalized with thin polydopamine layer on an in vitro model. 
XPS (X-ray photoelectron spectroscopy) is used to study the functionalization of CoCr. 
Ostegenicity is tested by real-time PCR for osteogenic markers and calcium deposition is tested 
by Alizarin red staining. The effects of functionalized BMP-7 peptide are then validated against 
growth factor and peptide control. 
4.2 Materials and Methods 
Materials 
 Mouse osteoblast MC3T3-E1, was obtained from ATCC, USA. The cysteine-tag 
functionalized BMP-7 peptide, Cys-miniPEG-TVPKPSSAPTQLNAISTLYF, the equivalent 
BMP-7 peptide probe, Cys-miniPEG-TVPKPSSAPTQLNAISTLYF-Lys-FITC and the control 
peptide, Cys-miniPEG-TIAPNFVKTLLYSSAPTPQS were synthesized by 1st BASE, Sg. PCR 
primers were synthesized by 1st BASE, Sg. mRNA RNeasy extraction kit was purchased from 
Qiagen, Germany. cDNA synthesis kit and PCR SYBR green master mix were purchased from 
Invitrogen, USA. Recombinant human BMP-7 and BMP-2, 10 μg were purchased from 
ABCAM, UK.  
Preparation of Substrates 
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 See chapter 3 Materials and Methods. Unbound is designated BMP-7 (intact unbound 
BMP-7 growth factor) and BMP-2 (intact unbound BMP-2 growth factor) for subsequent 
discussions. 
Characterization  
 X-ray photoelectron spectroscopy (XPS) was used to characterize the surface chemical 
composition of the CoCr foils [72]. The XPS, AXIS HSi spectrometer (Kratos Analytical Ltd, 
UK) with an AlKα X-ray source (1486.6 eV photons) was used and all binding energies (BEs) 
were referenced to the C 1s hydrocarbon peak at 284.6 eV. 
Determination of Bioconjugation 
 Cys-miniPEG-TVPKPSSAPTQLNAISTLYF-Lys-FITC probe was used to check the 
binding efficiency. This BMP-7 peptide probe with a fluorophore (FITC) acts as a direct ELISA 
to directly observed attachment onto the metal surface. A serial dilution was performed using a 
titration of 1 to 100 μg of the peptide probe onto the polydopamine coated CoCr substrate. After 
incubation for 2 hours, the surface was washed twice in PBS. Raw images were photographed 
with an Olympus IX-81 inverted epifluorescence microscope (Olympus, Japan). All digital 
images were processed with The Olympus Fluoview FV1000 software. ImageJ freeware (NIH, 
USA) was used to process the fluorescence intensity. The pictures were transformed to binary 
image via choosing a threshold where the threshold values were verified empirically [80]. A 




 Low passage mouse pre-osteoblast MC3T3-E1, American Tissue Culture Collection, 
USA were routinely cultured in 10% fetal bovine serum and 5% penicillin/streptomycin 
(Invitrogen, USA) in DMEM (Invitrogen, USA). The cells were kept at 37oC in a humidified 
environment of 5% CO2 with the changing of growth medium every couple of days. Trypsinized 
osteoblast were seeded on top of coated/uncoated 1 x 1 cm2 CoCr placed inside a 24-well plate at 
50,000/well in 1.0% fetal bovine serum and ascorbic acid. The CoCr substrates were removed 
and transferred to a new plate and only the cell layer fractions on the surface of the CoCr were 
harvested.  
Real Time Quantitative PCR 
 mRNA extraction was performed using the QIAshredder and RNeasy kit (QIAGEN, 
Germany). mRNA concentration was determined via nanodrop 1000 spectrophotometer (Thermo 
Scientific, USA).  cDNAs were synthesized using the Superscript vilo cDNA synthesis kit 
(Invitrogen, USA) using a standardized program (synthesis at 42°C for 1 hour and termination at 
80°C for 2 minutes) on iCycler thermal cycler (Bio-RAD, USA). Real-time quantitative PCR 
was performed using Express GreenER QPCR AB (Invitrogen) kit on Applied Biosystems One-
Step Plus machine. PCR experiments were performed in a volume of 10 μl, and primers were 
used at a final concentration of 0.2 μM in quintuplicates. Relative gene expression was 
performed using SYBR Green 2∆∆CT method calibrated to the housekeeping gene, GAPDH [93]. 
Normalization to untreated samples, calculation and standard errors were performed using the 
Applied Biosystems proprietary software and all PCR experiments. Primer sequences were 
obtained from literature and checked with BLAST (NCBI Nucleotide) or predicted via Primer 
Express 2 Software (Applied Biosystems). Primer sequences and annealing temperatures of are 
summarized in Table 4.1. Primers were synthesized by 1st BASE Asia, Sg. 
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Accession number Gene  Primer Sequences 
NM_008084 Mouse GAPDH 5’-GCACAGTCAAGGCCGAGAAT -3’(Forward) 
5’-GCCTTCTCCATGGTGGTGAA -3’ (Reverse) 
NT_039649 Mouse RUNX2 5’-CGAGTCATTTAAGGCTGCAA  -3’(Forward) 
5’- AGGCTGTTTGACGCCATAGT -3’(Reverse) 
NT_187033 Mouse Alkaline Phosphatase 5’-GCTGATTCCCAGGTTTT  -3’(Forward) 
5’- CTGGGCCTGGTAGTTGTTGT -3’(Reverse) 
NT_039240 Mouse osteocalcin 5’- CCTCAGTCCCCAGCCCAGATCC -3’(Forward) 
5’- CAGGGCAGAGAGAGAGGACAGG -3’(Reverse) 
 
Table 4.1 PCR primers for mouse osteogenic markers. 
 
Alizarin Red Staining (Proof of Concept) 
 Osteogenic induction was performed by adding 50 μg/ml ascorbic acid and 10 mM 
sodium β-glycerophosphate) to the osteoblasts for 3 weeks to induce mineralization. Alizarin red 
staining was used to detect the presence of calcium formation in the osteoblasts. The osteoblasts 
were then washed with PBS and post-fixed with 10% formaldehyde before incubating at room 
temperature for 15 minutes. The 10% formaldehyde was removed via three rinses with distilled 
water before Alizarin red staining. 1% alizarin red was added to the cell layers and incubated for 
20 min. Finally the cell layers were then washed with PBS before being photographed. 
Statistical Analysis 
 Samples were analyzed in quintuplicate per time point for every experimental condition. 
Shapiro–Wilk test was used to analyze the data for normal distribution whilst a one-way analysis 
of variance (ANOVA) post-hoc Tukey test was used to analyze the normally distributed data. 







Figure 4.1 XPS wide-scan spectra of the following: (A) CoCr, (B) CoCr-PDOP, (C) CoCr-








Table 4.2 Elemental composition* at the surface of the individual substrates (n =1) as 




 The XPS wide scan spectra of CoCr (A), CoCr-PDOP (B) and CoCr-PDOP-BMP-7 
peptide (C) are shown in Figure 4.1 with their corresponding surface elemental compositions in 
Table 4.2. In the wide scan spectrum of CoCr (Fig. 4.1A), the major components are C 1s (285 
eV), O 1s (530 eV) and Co 2p (780 eV). Elemental carbon background is usually present from 
inevitable hydrocarbon contamination and it was used as an internal reference at 284.6eV for 
calibrating peak positions. A small amount of N is also discernible and is probably the result of 










Figure 4.2 (A) CoCr-PDOP, (B) CoCr-PDOP-BMP-7 peptide 1 μg (C). CoCr-PDOP-BMP-7 
peptide 10 μg and (D) CoCr-PDOP-BMP-7 peptide 100 μg. The scale bar represents 1000 μm. 
The graph represents the titration of the bounded peptide probe concentrations from (A) to (D). 
(*) indicate statistical significance (P < 0.05) compared with CoCr-PDOP. Sample size of n=3 





Determination of Bioconjugation 
 There is no fluorescent signal on the pristine CoCr substrate (Fig. 4.2A). Positive green 
fluorescence signal can be observed with the CoCr-PDOP substrates after reaction with BMP-7 
peptide probe. Increasing fluorescence is detected at higher concentrations of the probe (Fig. 
4.2B-D). The fluorescence intensities are plotted as bar graph below the fluorescence pictures 
(Fig. 4.2). The highest fluorescence unit/concentration (peptide) ratio of the immobilized BMP-7 



















Comparison between BMP-7 and BMP-7 Peptide on Unbound in a 24-Well Plate Culture 
Flask 
 
Figure 4.3 Real time PCR Gene expression measured by real-time PCR on BMP-7, BMP-7 
peptide and BMP-7 control peptide after day 1 to 3 (n = 5). Relative quantities are normalized to 
untreated cells. Concentrations of growth factors/peptides are 10 µg/ml. (*) indicate statistical 




Comparison between BMP-7 and BMP-7 Peptide on Unbound in a 24-Well Plate Culture 
Flask 
 The optimum concentration of immobilized BMP-7 peptide as determined from the 
bioconjugation was 10 μg (Fig. 4.2). At 10 μg of BMP-7 peptide, increases the gene expression 
of osteogenic markers, OCN, ALP and RUNX-2 were observed. The gene expression was 
normalized to untreated osteoblasts. Time points at 1 to 3 days showed increases the gene 















Real Time PCR Bound BMP-7 Peptides  
 
Figure 4.4 Real time PCR Gene expression measured by real-time PCR on CoCr, CoCr-PDOP 
and CoCr-PDOP-BMP-7 peptide, CoCr-PDOP-control peptide and BMP-7 after day 1 to 3 (n = 
5). Relative quantities are normalized to CoCr.  Concentrations of growth factors/peptides are 10 
µg/ml.  (*) indicate statistical significance (P < 0.05) compared with CoCr. 
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Real Time PCR Bound BMP-7 Peptides 
  The optimum concentration of immobilized BMP-7 peptide as determined from the 
bioconjugation was 10 μg (Fig. 4.2). At 10 μg of BMP-7 peptide, increases the gene expression 
of osteogenic markers, OCN, ALP and RUNX-2. The gene expression was normalized to 
untreated osteoblasts. Time point at 1 to 3 days showed increases of gene expression of 





















Alizarin Red Staining 
Figure 4.5 Cell Morphology-Alizarin Red staining after 3 weeks incubation. 
 
Alizarin Red Staining 
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 After 3 week of osteogenic induction, the osteoblasts were stained with alizarin red. 
BMP-2 was used as a positive control which displayed red stained colonies indicating calcium 
deposition. BMP-7 growth factor and BMP-7 peptide showed less potent osteogenicity than 
BMP-2. No treatment and BMP-7 peptide were used as negative controls. The scale bar 
represents 200 μm. 
 
4.4 Discussion 
The effects of BMP-7 peptide [80] covalently attached to CoCr substrates via 
polydopamine chemistry on fibroblasts were explored in this study. Deposition of polydopamine 
on the CoCr substrate were vindicated under XPS by an increase in the N and C contents as 
shown in Fig. 4.1B and Table 4.2. The ratio of nitrogen-to-carbon (N/C) was found to be 0.121 
on CoCr-PDOP which corresponded to the hypothetical N/C ratio of 0.125 for dopamine. The 
total disappearances of photoelectron peaks unique to CoCr 2p (about 460 eV) corroborated the 
formation of the polydopamine thin film. Upon attachment of BMP-7 peptide on CoCr-PDOP 
(Fig. 4.1C), the N content increases again owing to the N-containing groups in this peptide.  
The bioconjugation assay was conducted to determine the surface distribution of the 
BMP peptide on the polydopamine coated substrates using fluorescence microscopy (Fig. 4.2). 
The peptide probe concentration of 10 μg/cm2 (Fig. 4.2C) has the best fluorescence signal-to-
noise ratio; i.e. exhibiting the higher fluorescent intensity over the surface area of the 1x1 cm2 of 
CoCr substrate. The fluorescent intensity is an arbitrary value as processed by IMAGE J. The 
substrate is a metal and when the images were captured under fluorescent microscope, it registers 
some background noise when processed under IMAGE J. Therefore, the bar graph was corrected 
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for background noise. These results verified the feasibility to graft BMP-7 peptide to the 
polydopamine biomimetic layer. 
Osteogenic markers are typically expressed by gene expression under induction of 
osteogenic markers. Common osteogenic markers used in this study are genes generally present 
in osteoblast, RUNX2, alkaline phosphatase and Osteocalcin [80]. The cells were tested without 
the presence of polydopamine and incubated with the BMP-7 peptide, the positive control BMP-
7 and the negative control, the scrambled control peptide (Fig. 4.3). Real time PCR results 
indicated that osteogenic markers are increased upon addition of BMP-7 and BMP-7 peptide 
compared to controls. This supports the feasibility of the BMP-7 peptide to induce osteogenicity 
as previously reported [80]. The functionalized susbstrates were also measured by real-time PCR 
which support the literature that bound BMP-7 peptide has osteogenic effects on osteoblasts. At 
day 3, bound BMP-7 peptide exhibited increased osteogenicity compared to BMP-7 (Fig. 4.4). 
This suggests that the effects of bound BMP-7 peptide localized the effects of BMP-7 peptide on 
the metal rather simple diffusion. 
Alizarin red staining showed (Fig. 4.5) that BMP-2 is more potent in osteogenesis than 
BMP-7. From the literature, BMP-2 expression in growing bone was less than in chondrocytes 
[94], hence addition of BMP-2 increases osteogenicity. Addition of osteogenic media for BMP-2 
treated osteoblast increases calcium deposition [95]. The effects of BMP-7 peptide and BMP-7 
growth factor were observed to act early (i.e. 1-3 days based on PCR results) on osteoblast than 





 This study serves to validate the osteogenicity of BMP-7 peptide based on an established 
BMP-7 peptide design by Zouani et al. [80] The XPS and bioconjugation studies proved that the 
BMP-7 peptide can be covalently grafted onto the CoCr surface. Real time PCR studies showed 
increasing gene expression of osteogenic markers, which validated the results reported by Zouani 















CHAPTER 5 Anti-Fibrosis Effect of BMP-7 Peptide Functionalization: An In Vitro Study 
on Cobalt Chromium Alloy 
5.1 Introduction 
 The enhancement of metallic implants with surface properties [83, 96] that can reduce 
post-operative fibrosis [32] is a paragon of osseointegration. Successful osseointegration of the 
metal implant is conditional upon osteoblasts attaching to the implant surface without an 
intervening collagen layer [44, 97-99]. Fibrous capsule formation around the cobalt chromium 
alloy (CoCr) implants [100, 101] results in very little restitution of normal bone tissue [33]. 
Excessive fibrous capsule formation at the bone implant interface [102] can prevent the CoCr 
implants to integrate into the surrounding bone and may also result in bone resorption 
independent of osteoclasts [103]. Clinically, post-operative fibrosis is an irreversible 
complication in surgery [104] and joint replacement procedures [105] which can result in 
implant loosening and failure of the implant or the adjacent bone [15]. The fabrication of 
implants with anti-fibrosis properties would be beneficial for surgical use during direct biological 
fixation to enhance bioactive implant-tissue reaction [15]. Studies are still lacking which 
investigate the role of anti-fibrotic factors immobilized on metallic implant surfaces for such 
purposes. 
  BMP-7 has been reported to be able to reduce fibrosis in cardiac, liver and renal tissues 
[106-108] but BMP-7 or its derivatives has not been specifically investigated for its anti-fibrosis 
effect on implant related fibrosis. More economical BMP peptides with osteogenic properties 
were developed due to the exorbitant cost of growth factors [80, 88]. BMP-7 peptide developed 
from the knuckle epitope of BMP-7 growth factor [80] was selected for this study as it was 
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previously known to activate BMP-7 signalling via vibration of BMP receptor II. To this BMP-7 
peptide [80], a cysteine amino acid was attached at the N terminal end and a mini-polyethylene 
glycol (miniPEG) was added as a spacer.  This cys-tag functionalized BMP peptide can then be 
conjugated via thiol directed chemistry. Therefore we now hypothesized that BMP-7 peptides 
may be covalently grafted onto metal using polydopamine chemistry [91] for antifibrosis 
properties.   
 Fibrosis is also a major occurrence in many human organs [46] and in biomaterial 
implants with or without inflammation [109]. TGF-β1 (Transforming growth factor beta-1) is 
known to elicit fibrosis specifically myofibroblasts or ACTA2 (Alpha Actin-2) [49]. We used an 
in vitro model where fibroblasts [110] were seeded onto the CoCr sheets and TGF-β1 was added 
to induce fibrosis. Functionalized BMP-7 peptide was assayed for its ability to down regulate 
fibrotic markers like ACTA2, COL1A1 (collagen, type 1, alpha 1) and fibronectin. The 
biological effects of the covalently grafted BMP peptide were then evaluated on embryonic 
mouse NIH/3T3 fibroblasts and the effects of the functionalized substrates for anti-fibrotic 
properties were analyzed.  
5.2 Materials and Methods 
Materials 
 Mouse fibroblasts (NIH/3T3, CRL-1658) were obtained from ATCC, USA. CellQuant-
MTT test kit for cell viability was acquired from BioAssay Systems, USA. Rabbit anti-mouse 
Collagen type 1A1, fibronectin, Phospho-Smad 1/5/8, Phospho-Smad 3 antibodies and Amicon-
Ultra 15 protein purification kit were purchased from Millipore, USA. Rabbit anti mouse 
ACTA2 antibody was bought from Lifespan Biosciences, USA. cDNA synthesis kit, PCR SYBR 
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green master mix, Biotin-XX Microscale Protein Labeling Kit, Protein Quant Sample Lysis Kit, 
TaqMan® Protein Assays Core Reagents Kit,  secondary antibodies Alexa Fluor® 488 goat anti-
rabbit and Alexa Fluor® 546 goat anti-rabbit were purchased from Invitrogen, USA. Dopamine 
(3,-4-dihyroxyphenylalanine) and Hoechst 33258, (bis-benzimide) pentahydrate nucleic acid 
stains were purchased from (Sigma-Aldrich, USA). Recombinant TGF-β1, 5 μg was purchased 
from BioVision, USA. Recombinant BMP-7, 10 µg was bought from ABCAM, UK. 
Preparation of Substrates 
 See chapter 4 Materials and Methods 
Characterization  
 See chapter 4 Materials and Methods 
Determination of Bioconjugation 
 See chapter 4 Materials and Methods 
Tissue Culture 
 Passage 5 Mouse fibroblasts (NIH/3T3) were routinely cultured in 10% Calf Serum and 
5% Penicillin/Streptomycin in DMEM [110]. Fibroblasts were grown at 37oC in a moist 
atmosphere of 5% CO2 with changing of growth media every couple of days. Trypsinized 
fibroblasts were seeded on top of coated/uncoated 1 x 1 cm2 CoCr placed inside a 24-well plate 
at 50,000 cells per well in 1% Bovine Calf Serum, DMEM and 100 μM of L-ascorbic acid 
(Wako, Japan). Cells were cultured and with/without the optimum concentration of 10 ng/ml 




 The fibroblasts were rinsed twice with Hank’s balanced salt solution (Invitrogen) and 
trypsinized after 24 hours to remove unattached cells. The trypsinized adherent fibroblasts were 
neutralized by addition of equal volume of DMEM with 10% Bovine Calf Serum after 5 minutes. 
The detached adherent fibroblasts were counted and analysed by using a Scepter (Millipore), 
coulter method based automated cell counter [112]. Attached fibroblasts on substrates are 
designated as number of cells/cm2. Proliferation of the fibroblasts attached onto the substrates 
was determined via measuring the total quantity of trypsinized fibroblasts at time points of 1, 3 
and 7 days. The quantity of adherent fibroblasts on the bottom surface of a similar culture well 
sans the CoCr substrate was used as a control and counted at the respective points in time.  
Cell Cytotoxicity 
 The viability of the NIH/3T3 fibroblast on the Cobalt chromium substrates was assessed 
with MTT assay following 1 week of culture. The MTT assay is based on the conversion of 
yellow coloured MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazoliumbromide) to purple 
coloured formazan by metabolically active cells as a direct function of mitochondrial activity. 
The MTT assay was done using the (BioAssay Systems, USA) kit following the manufacturer’s 
instructions. Briefly, a suitable quantity of MTT reagent was added to the cells at week 1 of 
culture on the different substrates and then incubated for 4 hours at 37oC. A suitable amount of 
solubilization solution was added to respective cultures and then gently mixed on an orbital 
shaker for 1 hour at room temperature. The intensity of the colour in each well was measured at 
570nm on an (TECAN) Infinite® 200 PRO absorbance plate reader. Results are reported as the 
means ± SD of five separate experiments. 
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Real Time Quantitative PCR 
 See chapter 4 Methods and Materials. Primer sequences and annealing temperatures are 
summarized in Table 1.   
 
 
Table 5.1 PCR primers for fibrosis markers. 
 
Protein Quantification 
 Protein quantification was performed using the TaqMan Protein assay, based on the 
method of Proximity Ligation Assay [113]. Cell layer samples were lysed with cell lysis solution 
(Life Technologies) containing protease inhibitor cocktail set I (Calbiochem). Antibodies 
specific to the protein of interest were biotintylated using Biotin-XX microscale protein kit. The 
biotintylated antibodies were dialyzed with Amicon-Ultra 15 protein purification kit to remove 
excess biotin. The biotintylated antibodies were made into probes using the TaqMan® Protein 
Assays Open Kit (Life Technologies). Probe specificity was checked using Forced Proximity 
Probe Test as recommended in the manufacturer’s protocol. The protein of interest was ligated 
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with the probes at room temperature and was then inactivated with proteases according to the 
manufacturer’s protocol.  The samples were then loaded into the MicroAmp® Fast Optical 96-
Well Reaction Plate and run with a typical fast cycle on a One Step Plus real time PCR machine. 
The data was then analyzed using the Proteinassist™ Software. 
Immunohistochemistry 
 Non-adherent cells were removed by rinsing twice with PBS and adherent cells were then 
fixed with a pre-chilled 2.5% paraformaldehyde (Sigma–Aldrich) for 15 minutes. The 
paraformaldehyde was removed by 3 washes with PBS for 5 minutes each. The samples were 
blocked with 3% w/v BSA (Sigma-Aldrich) in PBS for 30 minutes. TGF-β1 and BMP-7 activity 
were assayed via primary antibodies; rabbit anti-mouse Phospho-Smad 3 (Millipore) and rabbit 
anti-mouse Phospho-Smad 1/5/8 (Millipore) respectively at 1:200 dilution each. Primary 
antibodies were incubated for 90 minutes at room temperature. Secondary antibodies were goat 
anti-rabbit AlexaFluor 488 (Invitrogen) or goat anti-rabbit AlexaFluor 546 at 1:400 dilutions. 
Cell nuclei were counterstained with Hoechst 33258 dye (Sigma, USA) and mounted inverted 
with 50% glycerol/PBS on a coverslip. Images were captured with an Olympus IX-81 inverted 
epifluorescence microscope (Olympus, Japan). All digital images processed with The Olympus 
Fluoview FV1000 software. 
Statistical Analysis 
 Samples were analyzed in quintuplicate per time point for every experimental condition. 
Shapiro–Wilk test was used to analyze the data for normal distribution whilst a one-way analysis 
of variance (ANOVA) post-hoc Tukey test was used to analyze the normally distributed data. 




Surface Characterization  
 See Fig. 4.1 
Determination of Bioconjugation 
 See Fig. 4.2  
Cell Adhesion 
 
Figure 5.1 Cell Adhesion  
 Number of attached fibroblasts per cm2 on surfaces of CoCr, CoCr-PDOP and CoCr-
PDOP-BMP-7 peptide, CoCr-PDOP-Control peptide and BMP-7 substrates (n = 5). (*) indicate 





 Fibroblasts adhesion on CoCr and CoCr-PDOP are significantly greater than CoCr-
PDOP-BMP-7 peptide (Fig 5.1). Fibroblasts attached to the CoCr-PDOP-BMP-7 at 1 μg, 10 μg 




Figure 5.2 Fibroblasts proliferation on the surfaces of CoCr, CoCr-PDOP and CoCr-PDOP-
BMP-7 peptides, CoCr-PDOP-Control peptide and BMP-7 substrates were compared by 
measuring the number of adherent fibroblasts  at days 1, 3 and 7 (n = 5). (*) indicate statistical 







 Cell proliferation on CoCr and CoCr-PDOP are greater than CoCr-PDOP-BMP-7 peptide 
(Fig. 5.2). The addition of BMP-7 peptide significantly reduces the proliferation rate of 
fibroblasts at days 3 and 7. 
Cell Cytotoxicity 
 
Figure 5.3 MTT Assay/Cell Cytotoxicity 
 Cell viability measured by MTT assay on the control, CoCr, CoCr-PDOP, CoCr-PDOP-
BMP-7 peptide, CoCr-PDOP-Control peptide and BMP-7 substrates after 1 week (n = 5). (*) 






 Cell viability on the CoCr, CoCr-PDOP, CoCr-PDOP-BMP-7 peptide, CoCr-PDOP-
Control peptide and BMP-7 substrates were assessed using the MTT assay, to give an indication 
of the effect of the substrates on the survival and proliferation of the attached cells after 1 week 
of culture. As shown in (Fig. 5.3), no significant differences in viability of fibroblasts were 
observed on the CoCr, CoCr-PDOP and CoCr-PDOP-Control peptide substrates compared to 















Real Time PCR  
Figure 5.4 Gene expression measured by real-time PCR on CoCr, CoCr-PDOP and CoCr-
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PDOP-BMP-7 peptide, CoCr-PDOP-control peptide and BMP-7 after week 1 to 4 (n = 5). (*) 
indicate statistical differences (P < 0.05) normalized to CoCr-PDOP.    
Real Time PCR 
 At increasing concentrations of BMP-7 peptide, there were higher reductions of ACTA2, 
COL1A1 and fibronectin at week 1 to week 4. The gene expressions were normalized to TGF-β1 
treated fibroblasts on CoCr-PDOP substrate (Fig. 5.4 A-C). Week 1 showed higher reduction of 
fibrotic markers as compared to week 4 (Fig. 5.4 A-C). These reductions of fibrotic genes are 
















Figure 5.5 Fibrotic proteins measured by Taqman protein assay on CoCr, CoCr-PDOP-BMP-7 
peptide, CoCr-PDOP-Control peptide and BMP-7 after week 1, 2, 3 & 4 (n = 5). The proteins 
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were compared in fold change (linear) to CoCr-PDOP. (*) denote significant differences (P < 
0.05).  
Protein Quantification 
 The protein quantification is defined as linear fold change (Fig. 5.5 A-C) and is 
normalized to CoCr-PDOP. The fibrotic proteins were quantified from week 1 to week 4. CoCr-



















Figure 5.6 Immunohistochemistry 
Phospho-Smad 1/5/8 (A) indicates expression of BMP-7 activity and Phospho-Smad 3 (B) 
expression revealed TGF-β1 activity. The scale bar represents 200 μm. 
Immunohistochemistry 
 Phospho-Smad 1/5/8 (Fig. 5.6 A) presence indicates the activity of BMP-7 whereas 
Phospho-Smad 3 (Fig. 5.6 B) indicates the activity of TGF-β1.  The bioactivity of the BMP-7 
peptide immobilized on the polydopamine coated substrates was shown to be active at week 1 
and was not compromised. Phospho-Smad 3 served as a control to assay for TGF-β1 activity, 
which is not inhibited but remain in the cytosol of the cells. Phospho-Smad signalling is 
generally present inside the cytosol of the fibroblast. 
 
5.4 Discussion 
 The effects of BMP-7 peptide [80] covalently attached to CoCr substrates via 
polydopamine chemistry on fibroblasts were explored in this study. Deposition of polydopamine 
on the CoCr substrate were vindicated under XPS by an increase in the N and C contents as 
shown in Fig. 4.1B and Table 4.2. The ratio of nitrogen-to-carbon (N/C) was found to be 0.121 
on CoCr-PDOP which corresponded to the hypothetical N/C ratio of 0.125 for dopamine. The 
total disappearances of photoelectron peaks unique to CoCr 2p (about 460 eV) corroborated the 
formation of the polydopamine thin film. Upon attachment of BMP-7 peptide on CoCr-PDOP 
(Fig. 4.1C), the N content increases again owing to the N-containing groups in this peptide. The 
bioconjugation assay was conducted to determine the surface distribution of the BMP peptide on 
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the polydopamine coated substrates using fluorescence microscopy (Fig. 4.2). The peptide probe 
concentration of 10 μg/cm2 (Fig. 4.2C) has the best fluorescence signal-to-noise ratio. These 
results verified the feasibility to graft BMP-7 peptide to the polydopamine biomimetic layer. 
 Fibroblasts coming into direct contact with the immobilized peptides on the implant 
surfaces were analyzed for its biological activities. There was about a 20% decrease in fibroblast 
attachment on the CoCr-PDOP-BMP-7 peptide (10μg) over CoCr-PDOP (Fig. 5.1). There was 
approximately a 2-fold decrease in cell number on the CoCr-PDOP-BMP-7 peptide (10μg) 
compared to the CoCr-PDOP at day 3 and 7 cell proliferation studies (Fig. 5.2). These results 
suggest that the fibroblast proliferation rate was reduced by the BMP-7 peptide. However, the 
cytotoxicity/MTT (Fig. 5.3) assays suggest that the polydopamine was not toxic to fibroblast.  
Recently, the use of polydopamine was found to be safe for use in vivo and can even reduce 
cytotoxicity [114]. These results suggest that CoCr-PDOP-BMP-7 peptide substrates were not 
cytotoxic to fibroblasts, and the immobilized peptide on its surface can reduce the attachment 
and proliferation of fibroblasts.  
 The effects of immobilized BMP-7 peptide at the surface indicate that it reduced the 
proliferation of fibroblast. Besides recruitment of fibroblasts from the wound healing process and 
the resident fibroblasts, fibroblasts can also originate from the EMT phenomenon [106]. BMP-7 
is a promising candidate to use in metallic-bone interface as it also prevents (endothelial-
mesenchymal transition) EMT via TGF-β1 induction [115]. Based on qPCR results, 10 μg of 
BMP-7 peptide is sufficient to reduce the fibrotic markers compared to untreated samples (Fig. 
5.4). From the qPCR results Fig. 5, week 1 showed reduced fibrotic markers like ACTA2, 
COL1A1 and fibronectin. The effects of immobilized BMP-7 peptide at the CoCr surface 
suggest that BMP-7 peptide activity can last longer than the in vitro BMP-7 effect on fibroblasts. 
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The protein expression levels expressed similar profile (Fig. 5.5) to gene expression. The protein 
ACTA2 regulates myofibroblast [116]; therefore immobilized BMP-7 peptide can reduce 
myofibroblast differentiation via reduction of ACTA2. TGF-β1 is thought to produce α-smooth 
muscle actin or ACTA2 via EMT [111]. Moreover, TGF-β1 activity as expressed by expression 
of Phospho-Smad 3 is relatively unaffected (Fig. 5.6B). This is important as complete 
knockdown of TGF-β1 can have deleterious effects on normal cellular functions [54]. The 
expression of Phospho-Smad 1/5/8 (Fig. 5.6A) indicates that BMP-7 signalling is activated 
intracellularly, accumulating primarily in the cytosol.  
 BMP-7 peptide bioactivity is subjected to functional regulation by its receptors and co-
receptors. In this instance, BMP-7 peptide that we used binds to the extracellular domain of BMP 
receptor II and activates BMP-7 signalling via vibration of BMP receptor II. BMP-7 also targets 
a wide variety of fibrosis in different tissues/organs [54]. However, BMP-7 growth factor does 
not prevent [58] Bleomycin-induced adult human/mouse lung and skin specific fibrosis. The 
mechanism of BMP-7 opposing TGF-β1-mediated collagen induction in mouse pulmonary 
myofibroblasts was known to be mediated through Id2 protein [61] and other regulatory proteins 
in complex signalling pathways which are beyond the scope of this study.  
 Covalently immobilized peptides have been known to promote desirable cell substrate 
interactions [72]. The biological half-life of growth factors; when immobilized, they were 
reportedly to have release kinetics for 40 days [117] and up to 70 days [118]. Site-specific 
immobilization of peptides also protects against invasive ectopic bone formation, high local 
concentrations in the microenvironments and the problems associated with undesirable effects at 
locations beyond the implant site [117]. Therefore the immobilized BMP-7 peptide at the metal 
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surface has the benefit of restricting fibroblasts attachment, proliferation and fibrosis gene 
expression, hence improving implant integration. 
 There are limitations associated with testing using primary cells which may result with 
different findings from clinical evidences or in vivo model which histology can reveal fibrous 
encapsulation. Furthermore, in vitro models may not show complex cellular interaction between 
inflammatory or other adjacent cells which may affect release characteristics and inactivation of 
the BMP-7 from the surface. Based on our studies (Chapter 4) and literature [80], the 
functionalized peptide showed osteogenesis under osteogenic media induction. As the peptide is 
securely bound to the substrates via covalent bioconjugation hence there is no release of the 
peptide to the culture medium [117, 118].The use of this chemical conjugation process will result 
in the creation of strong covalent bonds and intermolecular interactions between the metallic 
substrates and the peptide. On the one hand, these intermolecular bonds of the coating cannot be 
easily disrupted by normal mechanical forces [90] encountered. On the other hand, during 
insertion of a press fit implant, such as a femoral component of a hip replacement, may 
potentially scraped off the coating by the prepared bone owing to the high mechanical forces.  
5.5 Conclusion 
 We covalently grafted the BMP-7 peptide onto the surface of CoCr and showed the anti-
fibrotic activity of the BMP-7 peptide and their capacity of reducing fibroblasts adhesion, 
proliferation and expression rate of fibrotic markers. Our results indicate that covalently grafted 
BMP-7 peptide can be used to reduce fibrosis on tissue implant interface. This application can be 




CHAPTER 6 Anti-Inflammation Effect of BMP-7 Peptide on CoCr 
6.1 Introduction 
 Osteoarthritis of the hip is a common musculoskeletal problem mainly affecting articular 
surfaces of the joint and subchondral bone [16]. Total hip replacement and hip resurfacing using 
metals remains the treatment of choice for osteoarthritis of the hip [2]. Cementless total hip 
arthroplasty is used in cases of rheumatoid arthritis where the rheumatic bone comes into contact 
with the metal implant [119]. The surface of the metallic implant offers a target for modification 
especially during direct biological (cementless) fixation [96]. Cobalt chromium alloy (CoCr) is 
one of the most commonly used orthopaedic metallic implant known for its resistance to wear 
and corrosion, but its metallic debris [97] is also known to illicit immune reaction. Despite the 
general inertness of CoCr implants used, the CoCr implant corrosion products or metallosis have 
been shown to be associated with, dermatitis, urticaria, and vasculitis [120, 121]. Inflammation 
of tissues surrounding metallic orthopaedic implants remains long-term, post-placement sequelae 
that can contribute to the failure of the implant [109, 122]. Inappropriate host responses like 
inflammation [50] surrounding the biomaterial [123] after implantation into the body are chiefly 
mediated by secretory products of monocytes and macrophages [124]. Inflammation can also 
induce a host of downstream problems like fibrosis [100, 101, 125], bone resorption [126] and 
osteolysis [127] which results in implant failure and revision surgery.  The enhancement of a 
metallic implant with surface properties [83, 96] that can prevent initial and chronic 
inflammation will improve implant integration. 
 Excessive accumulation of fibroblast and macrophages/monocytes at the repair site have 
been reported in cases of implant extrusion, chronic pain and subsequent aseptic loosening [102].  
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Post-operative inflammation of implants from major orthopaedic surgery like spinal [128] and 
joint replacement can result in patient pain and implant loosening. There is still a lack of studies 
investigating the anti-inflammation properties of metallic implants specifically immobilized with 
synthetic peptides. The conferment of enhanced anti-inflammative properties could offer 
improved clinical results and perhaps increase implant lifespan. In vitro inflammation models 
and studies have used macrophages to simulate inflammatory cytokine release. 
Lipopolysaccharides (LPS), is a bacterial toxin used to challenge macrophages to produce 
inflammatory cascade via the Toll-like receptor 4 (TLR-4) induced pathway of inflammation 
[129]. Using mouse macrophages/monocyte RAW 264.7, an in vitro model was created where 
macrophages were seeded onto the CoCr metal surface. LPS was introduced into the 
macrophages over a period starting from 1 hour to induce the LPS challenge or inflammation.  
 BMP-7 growth factor offers a promising anti-TLR-4 mediated properties [64] in addition 
to its proven osteo-inductive properties. BMP-7 has been reported to be able to reduce TLR-4 
[64] inflammation in arthritis and prevent degradation of cartilage [130]. Bioactive factors are 
generating interest for use to accelerate bone healing on implants [131]. Growth factors and 
peptides have been covalently grafted onto metallic surfaces to affect desired bone implant 
interface response [71, 72]. However due to its exorbitant cost, peptides (BMP peptides) with 
osteogenic properties were developed [80, 88]. A BMP-7 Peptide design was chosen as it has 
been shown to mimic osteogenic of properties of BMP-7 growth factor [80]. Synthetic polymers 
can covalently grafted onto metal using polydopamine chemistry [91]. Therefore we now 
hypothesized that BMP-7 peptides may be covalently grafted onto metal using polydopamine 
chemistry for anti-inflammation properties. 
97 
 
 BMP-7 peptide sequence [80] was synthesized with a cysteine amino acid at the N 
terminus with a mini-polyethylene glycol (miniPEG) as a spacer to produce a cys-tag 
functionalized BMP peptide. This peptide can be conjugated via thiol directed chemistry as 
previously described [92]. The insertion of a cys-tag at the N-terminus and the miniPEG spacers 
were chosen in order to reduce interference on the functional activities of the peptide. BMP-7 
anti-inflammatory properties were assayed for its ability to down regulate LPS induced 
inflammatory markers like TLR-4, TNF-α (Tumour Necrosis Factor alpha) and MCP-1 
(Monocyte Chemo-attractant Protein-1) [68]. The biological activities of the immobilized BMP 
peptide were then analyzed on mouse RAW 264.7 and the effects of the functionalized substrates 
for anti-inflammation properties were then investigated. 
 
6.2 Materials and Methods 
Materials 
 Mouse macrophages/monocytes RAW 264.7 were obtained from ATCC, USA. ELISA 
for mouse TNF-α and MCP-1 was purchased from Thermo Scientific, USA. ELISA for mouse 
TLR-4 was purchased from Cusabio, P.R. of China. Hoechst 33258, (bis-benzimide) 
pentahydrate nucleic acid stain was purchased from (Sigma-Aldrich, USA). Primary rabbit anti-
mouse Phospho-Smad 1/5/8 antibody was purchased from Millipore and primary rabbit anti-
mouse TLR-4 was purchased from Invitrogen, USA. BMP inhibitor recombinant Noggin was 
purchased from BioVision, USA. BMP-7, 10 µg was bought from ABCAM, UK. 
Preparation of Substrates 
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 See chapter 4 Materials and Methods 
Tissue Culture 
 Mouse macrophages/monocytes (RAW 264.7, TIB-71; American Tissue Culture 
Collection, USA) were routinely cultured in 10% FBS and 5% Penicillin/Streptomycin 
(Invitrogen) in RPMI (Thermo Scientific). The cells were incubated at 37oC in a humidified 
atmosphere of 5% CO2 with the growth medium changed every 2 days. Trypsinized 
macrophages/monocytes were seeded on top of coated/uncoated 1 x 1 cm2 CoCr placed inside a 
24-well plate at 50,000/well [132] in 10.0% FBS. Cells were cultured with or without the 
optimum concentration of 1 μg/ml LPS [133] (Sigma-Aldrich, USA). The CoCr substrates were 
removed and transferred to a new plate and only the cell layer fractions on the surface of the 
CoCr were harvested for PCR and the medium were analysed by ELISA.  
ELISA Cytokine and Chemokine Measurements 
 The media supernatants were collected at various time points [134] of 1 hour, 8 hours, 16 
hours, 24 hours and 48 hours following LPS induction [135]. Cell-free supernatants were frozen 
at -70oC until analyses were performed. Amounts of TNF-α, MCP-1 and TLR-4 were determined 
using enzyme-linked immunoassay. The samples were thawed, diluted in fresh RPMI 
1640/sample diluent and processed according to the manufacturer’s protocol. The optical density 
was measured in an ELISA reader at 450 nm and corrected at 550 nm. Standard curves were 
created using four parameter logistic curve-fit (Softmax Pro 2.4) [136]. The intensity of the 
colour in each well was measured at 450 nm and subtracted from 550 nm on an (TECAN) 
Infinite 200 PRO absorbance plate reader. Cells were counted using a Scepter automated cell 
counter (Millipore, USA) and the protein concentrations were normalized to 50,000 cells. 
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Results are reported as the means ± SD of five separate experiments. Concentration of the 
cytokines and chemokines were determined from the standard curve. 
Real Time Quantitative PCR 
 See chapter 4 Materials and Methods. Primer sequences are summarized in Table 1.  
 
Table 1 PCR primers for inflammation markers. 
 
Immunocytochemistry 
 Non-attached cells were removed by washing twice with PBS and attached cells were 
then fixed with a pre-chilled 2.5% paraformaldehyde (Sigma–Aldrich) for 15 minutes. The 
paraformaldehyde was removed by 3 washes with PBS for 5 minutes each. The samples were 
blocked with 3% w/v BSA (Sigma-Aldrich) in PBS for 30 minutes. Primary antibodies used 
were as follows (dilution factor) BMP-7 activity were assayed via primary antibodies: rabbit 
anti-Phospho-Smad 1/5/8 (Millipore) respectively at 1:200 dilutions each. LPS activity was 
assayed via primary antibodies: rabbit anti-TLR-4 (Invitrogen) respectively at 1:200 dilutions 
each. Primary antibodies were incubated for 90 minutes at room temperature. Secondary 
antibodies were goat anti-rabbit AlexaFluor 488 (Invitrogen) or goat anti-rabbit AlexaFluor 546 
at 1:400 dilutions. Cell nuclei were counterstained with Hoechst 33258 dye (Sigma, USA) and 
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mounted inverted with 50% glycerol/PBS on a coverslip. Images were captured with an Olympus 
IX-81 inverted epifluorescence microscope (Olympus, Japan). All digital images processed with 
The Olympus Fluoview FV1000 software. 
 
Inhibition Assay 
 The cells were seeded onto a 24-well plate at 50,000 cells per well. The cells were then 
incubated with 1 µg/mL of recombinant Noggin (BioVision, USA) with LPS for 24 hours. This 
was followed by gene expression described under the real-time PCR section. 
 
Unbound BMP-7 Peptide Titration 
 The cells were seeded onto a 24-well plate at 50,000 cells per well. The cells were then 
incubated with 1 µg/mL of LPS (Sigma-Aldrich, USA) for 24 hours. This was followed by gene 
expression described under the real-time PCR section. 
 
Statistical Analysis 
 At least five samples per time point for each experimental condition were used. The data 
were tested for normal distribution by Shapiro–Wilk test. One-way analysis of variance 
(ANOVA) post-hoc Tukey test was used to assess the normally distributed data and the results 







ELISA of Pro-Inflammatory Cytokines and Chemokines 
 
Figure 6.1 Mouse TLR-4, TNF-α and MCP-1 proteins were release from RAW264.7 after treatment with 
LPS. TLR-4, TNF-α and MCP-1 was measured by ELISA at time points of 1 hour, 8 hours, 16 hours, 24 






 There is no significant reduction of TLR-4, TNF-α and MCP-1 at 1 hour time point by 
BMP-7 peptide. Expression of TLR-4, TNF-α cytokine and MCP-1 chemokine release are 
reduced in CoCr-PDOP-BMP-7 peptide compared to RAW264.7 cells seeded on CoCr, CoCr-
















Real time PCR  
 
Figure 6.2 Inflammation related gene expression measured by real-time PCR on the controls, 
CoCr, CoCr-PDOP, CoCr-PDOP-BMP-7 peptide and CoCr-PDOP-control peptide substrates 
after 1 hour, 8 hours, 16 hours, 24 hours and 48 hours (n = 5). The assay shows that immobilized 
BMP-7 peptide reduces expression of inflammation related genes TLR-4, TNF-α and MCP-1. 
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There is significantly lower expression of inflammation markers observed in the CoCr-PDOP-
BMP-7 peptide compared to the LPS treated RAW 264.7 on CoCr and CoCr-PDOP. (*) denote 
significant differences (P < 0.05). 
 
Real Time PCR 
 The optimum concentration of immobilized BMP-7 peptide as determined from the 
bioconjugation was 10 μg (Fig. 4.2). At 10μg of BMP-7 peptide, reduces the expression 
inflammation markers, TNF-α, MCP-1 and TLR-4 starting at 8 hours. The gene expression was 
normalized to LPS treated RAW264.7 grown on CoCr (Fig. 6.2A-C). Time point at 8 hours 
showed higher reduction of inflammatory markers as compared to time point at 1 hour and 
controls (Fig. 6.2A-C). During 8 hours at 10 μg peptide concentration, there is 2-fold reduction 
of TNF-α, 2-fold-reduction of MCP-1 and 2-fold-reduction of TLR-4 compared to LPS treated 
RAW 264.7 on CoCr-PDOP. Other time points of 16, 24 and 48 hours showed varying reduction 











Figure 6.3 Immunofluorescent staining reveals that the RAW 264.7 cells show expression of 
inflammation marker, (A) TLR-4. Phospho-Smad 1/5/8 (B) expression indicates expression of BMP-7 
activity. Blue stains for Hoechst 33258, a nucleus DNA stain, red for TLR-4 and green for Phospho-
SMAD 1/5/8. The scale bar represents 50 μm. 
Immunohistochemistry 
 During 24 hours at 10 μg of BMP-7 Peptide, TLR-4 protein expression was found to be 
reduced compared to LPS treated CoCr (Fig. 6.3A). Phospho-Smad 1/5/8 signalling is generally 






Figure 6.4 Inflammation related gene expression measured by real-time PCR on the cells 






 During 24 hours at 10 μg of BMP-7 Peptide with 1µg/ml of Noggin, there is no reduction of 
inflammation markers. (Fig. 6.4A-C) 




Figure 6.5 Inflammation related gene expression measured by real-time PCR on the cells after 
24 hours (n=5). 
Unbound BMP-7 Peptide Titration 
 BMP-7 peptide exhibits 2-fold reduction of inflammation markers (Fig. 6.5A-C) at 10 
µg/ml concentration compared to controls, both non-treatment and CoCr-PDOP control peptide. 
The unbound BMP-7 peptide exhibit similar reduction of inflammation markers compared to full 
length BMP-7 growth factor.    
 
6.4 Discussion 
 In our in vitro model, we determined the effects of CoCr functionalized with BMP-7 
peptide on inflammation in mouse monocyte/macrophages. BMP-7 peptide [80] was chosen to 
be covalently grafted to CoCr substrates via polydopamine chemistry [90, 91]. The chemical 
composition of the substrates at various stages of surface modification was determined by XPS 
to validate the stepwise functionalization procedures. Positive coating of polydopamine on the 
CoCr substrate was indicated by an increase in the N and C contents as shown in Fig. 4.1B and 
Table 4.1. The binding of BMP-7 peptide on CoCr-PDOP (Fig. 4.1C), was indicated when the 
nitrogen content increases again due to the N-containing groups in this protein. A bioconjugation 
assay was conducted to assess the surface distribution of the BMP peptide on the polydopamine 
coated substrates. A very strong fluorescence was observed on the peptide probe coated onto the 
CoCr surface under fluorescence microscopy. These results (Fig. 4.2) showed the random 
dispersion of the immobilized peptide and demonstrated the ability to bind these amino acid 
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groups to the biomimetic layer. The peptide probe concentration of 10 μg/cm2 has the optimal 
fluorescent intensity/concentration ratio (Fig. 4.2C).  
 The biological activity of the immobilized peptide plays a critical role during implant 
integration as cells come into direct contact with the implant surface. The use of polydopamine 
was found to be safe to use in vivo and can even reduce cytotoxicity [114]. Macrophages seeded 
on CoCr have been known to release cytokines and chemokines following LPS challenge [137]. 
ELISA was used to measure the release of cytokines and chemokines released into the media by 
macrophages in contact with the surface of implants. TLR-4 expression (Fig. 6.1A) showed an 
initial spike following LPS induction but was reduced after 8 hours. There is similar reduction of 
release of cytokine TNF-α (Fig. 6.1B) and chemokine MCP-1 (Fig. 6.1C) on macrophages 
seeded on CoCr-PDOP-BMP-7 peptide. The mRNA quantification of TNF-α, MCP-1 and TLR-4 
expression via qPCR (Fig. 6.2A-C) showed general reduction of inflammatory markers 
compared to controls. TNF-α is also known to induces apoptosis in human naïve and memory 
CD8+ Tcells [138]. BMP-7 is known to reduce chemokine MCP-1 in human mesangial cells [76, 
77] and reducing TLR-4 activity [64]. Other studies have suggested that reprogramming of 
macrophage into an anti-inflammatory M2 phase could be an explanation in the reduction of 
inflammation by BMP-7 [75].  
 The expression of Phospho-Smad 1/5/8 (Fig. 6.3B) indicates that BMP-7 signalling is 
activated intracellularly, accumulating primarily in the cytosol. BMP-7 activity correlates with 
reduction of TLR-4 protein expression (Fig. 6.3A). BMP-7 peptide bioactivity is subjected to 
functional regulation by its receptors and co-receptors. BMP-7 peptide exerts its biological effect 
on the macrophages/monocytes through BMP receptors and receptor associated Smads or 
directly by activating MAPKs (p38 MAPK) via transforming growth factor β–activated kinase 
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[64]. The bioactivity of BMP-7 generally is determined by the availability of Phospho-Smad 
1/5/8 binding sites on the molecule. The inhibition via noggin inhibits BMP-7 peptide activity to 
prevent inflammation (Fig. 6.4A-C). BMP-7 peptide displayed dose-dependence in reduction of 
inflammation (Fig. 6.5A-C). At lower concentration like 1 µg/ml, BMP-7 peptide displayed 
moderate reduction of inflammation markers, whereas at higher concentration, BMP-7 peptide 
displayed about 2-fold reduction in inflammation markers.   
 The benefits of covalently immobilized peptides have been shown to promote desirable 
cell substrate interactions [72] and increased cell adhesion onto the substrate surface [139]. This 
is contrasted with the ineffective method of direct injection of growth factor in solution into the 
regeneration site, as the injected growth factor is rapidly dispersed [80] or in a conventional 
collagen sponge [140]. Covalent binding of bioactive factors also has the potential to reduce 
diffusion of the protein away from the regeneration site [141]. In general, the biological half-life 
of peptide is shorter, but an immobilized peptide may have a longer half-life of up to 40 days 
[117] and demonstrated a release kinetics up to 70 days [118]. Immobilized peptides also avoid 
disadvantageous effects such a high levels of factors in the local microenvironments and the risk 
of undesirable effects at locations beyond the implant site [117]. Therefore the covalently 
localized BMP-7 peptide at the metal-body interface has the benefit of reducing macrophage 
activity and cytokine release. Together, with the clinically proven bone regenerating properties 
of BMP-7, our study suggests that covalently bound BMP-7 peptide on CoCr surface can restrict 
inflammation.  Hence, covalently bound BMP-7 peptide on CoCr surface can be used in 





 In our study BMP-7 peptide anti-inflammation properties was adapted for biomaterial 
application. We covalently grafted the BMP-7 peptide onto the surface of CoCr and showed the 
anti-inflammation activity of the BMP-7 peptide and their capacity of reducing inflammatory 
cytokine and chemokines. Our results highlighted the fact that the BMP-7 peptide can be used to 
















CHAPTER 7 Conclusion of Study 
 Bioengineering and tissue engineering methods are increasingly studied and translated 
into clinical use to treat musculoskeletal disease. Although a very lengthy process of getting 
research from bench to bedside, current FDA approved drugs or biologics offers an opportunity 
to be improved and become more cost effective. The ever growing need for cheaper medical 
intervention coincides with the ever ageing population as human lifespan continues to increase. 
With increase age, chances to develop musculoskeletal disease like joint and back problems 
increases. In addition, autoimmune and degenerative diseases like rheumatoid arthritis and 
osteoarthritis also increases with age. Younger patients like athletes owing to active lifestyle 
often developed musculoskeletal problems owing to overuse or accidents. Therefore there is a 
growing need of using fast and effective intervention to treat these problems. Metallic implants 
are effective treatments for joints problems as it offers immediate structural support and restore 
mechanical functions especially in total joint replacements. Metals also acts as a ready-made 
permanent scaffold unlike biodegradable scaffold that cannot support high mechanical loading.   
 Fixation or fusion of metal implants onto bone usually employs chemicals like bone 
cement (a grouting agent) can offer intermediate longevity of the implant. Ideally, for implants to 
last a lifetime requires full osseointegration into the skeleton is required. To do so requires 
adherence of bone cells onto the metal implant. However, during the repair or wound healing 
process, the body will increase inflammation to clean the area of infection and dead cells. The 
body also recognizes the metal implant as a foreign body and encapsulates it away from direct 
contact with the adjacent tissue. This fibrosis on joints owing to the amount of movement can 
results in micromotion, where the implant slides against the surrounding tissue. Fibrosis although 
can be used on porous metal implants, fibrosis is generally a bad outcome as it isolates cell from 
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the implant and prevents nutrients to those isolated cells. In addition, metal debris can also 
developed and trigger inflammation response. Therefore, strategies are needed to reduce fibrous 
encapsulation resulting and the chronic or excessive inflammation response. In addition, 
fibroblast and macrophage/monocyte adhesion can cause osteolysis and bone resorption. 
Revision to address the problems of bone loss and aseptic loosening is both costly in time and 
economic burden to the patients. Revision surgery also increases morbidity in elderly patients. 
Therefore, to prevent problems like fibrosis and inflammation, bioactive strategies can be used to 
improve osseointegration into the skeleton and restore joint functions. 
   Fixation or bonding of bone to implant is a problem that affects orthopaedic surgery. 
Various designs of implants have been used that varies the surface roughness and porosity of the 
implant. Other strategies involved BMPs especially FDA approved BMP-2 and BMP-7 growth 
factors are two of the greatest factors to promote fast bone healing. BMPs acts via osteoinduction 
by promoting osteoblast proliferation and calcification. However, the greatest drawback of 
BMPs is the cost which limits its universal use. Strategies to mimic BMPs are peptides are 
increasingly studied as an alternative to BMP growth factors. In our studies, BMP-7 peptide is 
adapted and immobilized using existing technology. Cobalt Chromium is used as in our model, 
its smooth surface causes fibrosis compared to titanium. In addition, osteoblast did not grow as 
well on CoCr as opposed to titanium, as cobalt chromium does not form an oxide layer unlike 
titanium. Existing BMP-7 is adapted and validated for its osteogenicity. The BMP-7 peptides are 
then covalently bound to the CoCr surface. The composition of the polydopamine 
functionalization on CoCr is assayed using XPS and the deposition of BMP-7 peptide is 
ascertained by a probe in a bionconjugation assay. Models of fibrosis using TGF-β1 induction of 
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fibrosis and LPS-induction of inflammation were used to test the effectiveness of this BMP-7 
peptide.  
 Our results suggest covalently bound BMP-7 peptide can improve osseointegration. 
Compared to unbound peptides, covalently bound peptides, can increase peptide bioactivity for 
more than 4 weeks. Therefore, this allowed sufficient time for the bioactivity of the peptide’s 
function to take effect. In our studies, BMP-7 peptide can limit TGF-β1 induced fibrosis for up 
to 4 weeks. In addition, BMP-7 peptide can limit LPS induced inflammation up to 48 hours. 
Together with the osteogenic inducing properties, covalently immobilized BMP-7 peptide shows 
promise to be used in orthopaedic surgery to control adverse outcome in metallic implants. 
 The approved function of BMP-7 by the FDA are chiefly for the i) treatment of acute 
tibial fractures treated with intramedullary fixation and (ii) treatment of long bone non-union. 
The broad spectrum effects of BMP-7 based on other disciplinary studies on other organs/tissues 
suggests that these additional function of BMP-7 can be harnessed to modulate against adverse 
effects like inflammation and fibrosis. The osteogenic effect of BMP-7 is less than BMP-2 when 
under osteoinduction as proven by our studies and in literature. In vivo studies of polydopamine 
suggest the polydopamine can be used safely in vivo. As an interface between metal implant and 
bone, polydopamine a natural chemical based on barnacle biochemistry can be used as an anchor 
to promote osseointegration of implant into bone. The anti-inflammation and anti-fibrosis 
property of BMP-7 peptide allows it to be used to accelerate osseointegration and improved 





CHAPTER 8 Recommendations: For Future Work 
 Immobilized BMP-7 peptide using polydopamine on CoCr substrate allows the study of 
cellular response in vitro. The work of this thesis had looked at individual cell types separately 
particularly osteoblast, fibroblast and macrophage/monocytes.  Possible future works, are we can 
look at co-culture of these different cell combinations and analyzing/sorting the cell populations 
using flow cytometry. A direct follow up of this work is the application of immobilized BMP-7 
peptide in surgical dressing for anti-fibrosis.  
 Other anti-fibrosis or anti-inflammation agent particularly anti-TNF-α biologics or anti-
TGF-β1 biologics can also be studied. These biologics can be used to study the effects on 
fibroblast, macrophage/monocytes and osteoblast. Peptides or monoclonal antibodies can also be 
synthesized and immobilized using polydopamine to produce a bioactive substrate. Perhaps the 
peptides or drugs which can promote apoptosis [142] of fibroblasts can also be explored. The 
cellular responses can then be analyzed using the methods covered in this thesis.  
 An in vivo model using canine or rabbit can also be studied. Ostectomy or bone defect 
model to measure the amount of fibrosis formation and level of osseointegration can be used to 
test the anti-fibrosis/anti-inflammation factors. The data generated from the in vivo model can 
further improve on the fabrication of bioactive substrate, particularly the dose-response effect 
and optimum level of polydopamine coating.  
 The complex process of osseointegration, also suggest we can also look at the role of 
osteoclast cells in implant related bone resorption and bone remodelling. Anti-bone resorption 
techniques can also be looked at to improve osseointegration of implants. Other work can 
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